# Chapter 18: Schizoaffective Disorder

# Chapter 5: The Biological and Neurological Basis of Schizoaffective Disorder

## Introduction

Schizoaffective disorder represents one of the most complex and diagnostically challenging conditions in modern psychiatry (Miller et al., 1991; Marneros, 2012). First described by Kasanin in 1933, it occupies a nosological space between schizophrenia and mood disorders, characterized by a unique admixture of psychotic and affective symptoms (Tso et al., 2010; Kasanin, 1933). The defining feature of the disorder is the concurrent presence of symptoms meeting criteria for a major mood episode (major depressive, manic, or mixed) and the active-phase symptoms of schizophrenia (Tso et al., 2010; Miller et al., 1991). Critically, a formal diagnosis requires a period of at least two weeks where delusions or hallucinations are present in the absence of a prominent mood episode, establishing a psychotic process that is not merely an extension of severe mood dysregulation (Tso et al., 2010; Mir et al., 2022). This diagnostic stipulation helps to differentiate schizoaffective disorder from mood disorders with psychotic features (Steffens et al., 2013; Marneros, 2012).

The disorder is further subdivided into a bipolar type, where manic or mixed episodes are part of the clinical picture, and a depressive type, where only major depressive episodes co-occur with psychotic symptoms (Tso et al., 2010; Marneros, 2012). This heterogeneity poses significant challenges to understanding its underlying pathophysiology (Maj & Perris, 1985). From a biological and neurological perspective, schizoaffective disorder is often conceptualized as existing on a continuum between schizophrenia and bipolar disorder (Marneros, 2012; Ciompi, 1984). This perspective suggests that its neurobiological underpinnings may represent an overlap, an intermediate state, or a unique combination of the mechanisms implicated in both schizophrenia spectrum disorders and primary mood disorders (Kasanin, 1933; Marneros, 2012; Maj & Perris, 1985).

The clinical presentation of schizoaffective disorder involves a confluence of symptoms from distinct psychiatric domains. The psychotic component mirrors that of schizophrenia, encompassing positive symptoms such as delusions (fixed false beliefs) and hallucinations (perceptions without external stimuli), as well as negative symptoms like avolition, anhedonia, and affective flattening (Buckley & Foster, 2014; Pereira, 2021; Tso et al., 2010; Miller et al., 1991). Concurrently, patients experience profound disturbances in mood regulation characteristic of affective disorders (Bains et al., 2021; Tso et al., 2010). These can manifest as manic episodes, defined by abnormally elevated, expansive, or irritable mood and increased energy (Thomas, 2003; Mir et al., 2022; Belmaker, 2004), or as major depressive episodes, characterized by persistent low mood, loss of interest or pleasure (anhedonia), and associated vegetative and cognitive symptoms (Bains et al., 2021; Sheets & Brosse, 2010; Peveler, 2002).

Given the absence of definitive biological markers for schizoaffective disorder, this chapter aims to synthesize our current understanding by drawing upon research into the neurobiological substrates of its constituent syndromes: psychosis and mood dysregulation. By examining the neurobiological systems, genetic factors, and structural and functional brain abnormalities associated with schizophrenia and mood disorders, we can construct a plausible, albeit inferential, model of the pathophysiology of schizoaffective disorder. This approach acknowledges the disorder's complexity and the current limitations in the research literature, while providing a comprehensive, evidence-based framework for understanding its biological and neurological basis (Marneros, 2012; Maj & Perris, 1985). We will explore the implicated neurotransmitter systems, neural circuits, genetic predispositions, and developmental trajectories that contribute to this severe and persistent mental illness (Wright & Burns, 2002).

## Neurobiological Systems

The hybrid symptomatology of schizoaffective disorder, combining both psychotic and affective elements, strongly suggests a complex dysregulation across multiple neurobiological systems (Tso et al., 2010; Marneros, 2012). While research directly targeting the neurobiology of schizoaffective disorder is limited, a comprehensive understanding can be extrapolated from the extensive investigation into its component illnesses: schizophrenia and mood disorders (Maj & Perris, 1985; Marneros, 2012). The primary systems implicated include dopaminergic, serotonergic, noradrenergic, and glutamatergic pathways, which are fundamentally involved in regulating thought, perception, mood, and arousal (Fiar et al., 2012).

### Dopaminergic Systems and Psychosis

The dopamine hypothesis has been a cornerstone of schizophrenia research for decades, positing that an excess of dopamine activity, particularly in mesolimbic pathways, underlies positive psychotic symptoms such as hallucinations and delusions (Buckley & Foster, 2014; Juckel & Heinz, 2004). Since these symptoms are a defining feature of schizoaffective disorder, dysregulation of the dopamine system is considered a central pathophysiological mechanism (Tso et al., 2010; Jibson et al., 2004). The therapeutic efficacy of antipsychotic medications, which primarily act as antagonists at dopamine D2 receptors, provides strong pharmacological evidence for this hypothesis (Janicak, 2014; Marder, 1996; Watanabe, 2007). In patients with schizophrenia, hyperactivity of the dopamine system, especially involving the D2 receptor, is thought to be critical to the expression of positive symptoms (Dodd, 2007). By extension, this mechanism is highly relevant to the psychotic dimension of schizoaffective disorder (Marneros, 2012).

Substance-induced psychoses, particularly those caused by stimulants like amphetamines and cocaine, which increase synaptic dopamine, can produce a clinical picture resembling the positive symptoms of schizophrenia or the psychotic features of a manic episode (Brust, 2002; Henning et al., 2019; Avellaneda Ojeda et al., 2023). This provides further evidence that dopaminergic hyperactivity is a common pathway for the expression of psychosis, regardless of the primary diagnosis (Janicak, 2014; Mauri, 2016). The observation that antipsychotic medications are effective in treating acute psychosis irrespective of its cause—be it schizophrenia, bipolar mania, or substance-induced—reinforces the central role of dopamine dysregulation (Zolas & Sher, 2013; Battaglia et al., 2007). Conversely, some evidence suggests that negative and cognitive symptoms in schizophrenia may be related to a deficit of dopamine activity in prefrontal cortical regions (hypofrontality), indicating a more complex, region-specific dysregulation of the dopamine system (Dodd, 2007; Tamminga et al., 1998). This dual-pathway model of dopamine dysfunction—hyperactivity in subcortical limbic regions and hypoactivity in the prefrontal cortex—may also apply to schizoaffective disorder, potentially explaining the co-occurrence of positive symptoms with negative symptoms like avolition and affective flattening (Buckley & Foster, 2014; Tso et al., 2010; Pavlichenko, 2018).

### Serotonergic and Noradrenergic Systems in Mood Regulation

The affective component of schizoaffective disorder points to the involvement of neurotransmitter systems critically implicated in mood disorders, primarily serotonin (5-HT) and norepinephrine (Fiar et al., 2012; Anisman et al., 2005). The monoamine hypothesis of depression posits that a functional deficiency in these neurotransmitters contributes to depressive episodes (Potter & Goldstein, 2004; Coppen & Swade, 1988). Depressive symptoms such as persistent low mood, anhedonia, fatigue, and sleep disturbances are core to major depressive disorder and the depressive phase of both bipolar and schizoaffective disorder (Bains et al., 2021; Tso et al., 2010; Kennedy, 2008).

The efficacy of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in treating depression provides strong support for the involvement of these systems (Bains et al., 2021; Montgomery et al., 1993; Fava et al., 2002). These agents work by increasing the synaptic availability of serotonin and/or norepinephrine, thereby alleviating depressive symptoms (Potter & Goldstein, 2004; Fiar et al., 2012). The development of serotonin syndrome, a potentially life-threatening condition caused by excessive serotonergic activity from medication combinations, underscores the powerful influence of this system on mental state, autonomic function, and neuromuscular activity (Scotton et al., 2019; Bostankolu et al., 2014).

In the context of schizoaffective disorder, the interaction between serotonin and dopamine systems is of particular interest. Atypical (second-generation) antipsychotics often possess antagonist activity at serotonin 5-HT2A receptors in addition to their D2 receptor blockade (Janicak, 2014; Gerlach et al., 2014). This dual action is thought to contribute to their efficacy against both positive and negative symptoms and may also confer mood-stabilizing properties (Watanabe, 2007; Gerlach et al., 2014). This suggests that a complex interplay between dopaminergic and serotonergic systems may underlie the unique symptom profile of schizoaffective disorder, where psychotic and mood symptoms are inextricably linked (Marneros, 2012). Noradrenergic dysfunction is also implicated, particularly in symptoms like fatigue, loss of energy, and poor concentration, which are common in depression and represent a "noradrenergic symptom cluster" that may respond less well to purely serotonergic agents (Briley, 2011; Kennedy, 2008).

### GABAergic and Glutamatergic Systems and Neural Excitability

The balance between inhibitory (gamma-aminobutyric acid, GABA) and excitatory (glutamate) neurotransmission is fundamental to overall central nervous system stability (Löscher, 2009). Dysregulation in these systems is central to the pathophysiology of epilepsy, where abnormal, excessive, or synchronous neuronal activity leads to seizures (Silver & Airoldi, 2016; Chen & Wasterlain, 2006). There is growing interest in how imbalances in this excitatory/inhibitory equilibrium may contribute to psychiatric disorders, including the psychotic and manic symptoms seen in schizoaffective disorder (Löscher, 2009).

Conditions of extreme CNS hyperexcitability, such as alcohol withdrawal syndrome, are characterized by symptoms like agitation, anxiety, tremor, and, in severe cases, seizures and delirium (Saitz, 1998; Yersin, 1999; Moroi et al., 2018). These symptoms arise from the brain's adaptation to the chronic depressant effects of alcohol, leading to a hyper-excitable state upon withdrawal, partly mediated by downregulation of GABA-A receptors and upregulation of NMDA glutamate receptors (Becker & Redmond, 2002; Yersin, 1999). The therapeutic effectiveness of benzodiazepines, which are positive allosteric modulators of the GABA-A receptor, in treating both alcohol withdrawal and the agitation associated with acute psychosis and mania highlights a shared mechanism related to GABAergic function (Saitz, 1998; Pitchot et al., 2013).

Furthermore, catatonia, a psychomotor syndrome that can occur in schizophrenia, bipolar disorder, and schizoaffective disorder, is characterized by motor abnormalities and is also thought to involve perturbations in GABAergic and glutamatergic transmission (Zutshi et al., 2007; Yarlagadda et al., 2007). The dramatic response of catatonic symptoms to GABA-A modulators like lorazepam supports this link (Cottencin et al., 2009; Singh & Akinyemi, 2017). The glutamate hypothesis of schizophrenia suggests that hypofunction of the NMDA receptor could lead to both positive and negative symptoms (Becker & Redmond, 2002; Lawrence et al., 2015). This provides a compelling framework for understanding how a fundamental imbalance in excitatory/inhibitory signaling could contribute to the broad spectrum of symptoms observed in schizoaffective disorder, from the psychomotor agitation of mania to the cognitive deficits and psychotic experiences that define the illness (Löscher, 2009; Fiar et al., 2012).

## Genetic and Molecular Basis

The etiology of schizoaffective disorder, like that of schizophrenia and bipolar disorder, is understood to involve a substantial genetic component interacting with environmental factors (Moster et al., 2016; Tiller & Schweitzer, 2010). Although specific causal genes have not been definitively identified for schizoaffective disorder, its position as a diagnostic entity bridging psychotic and affective illnesses suggests that its genetic architecture likely involves a complex interplay of vulnerability genes associated with both of these parent disorders (Marneros, 2012; Maj & Perris, 1985).

### Heritability and Familial Risk

Family, twin, and adoption studies have consistently demonstrated that both schizophrenia and bipolar disorder are highly heritable (Buckley & Foster, 2014; Winokur, 1970; Cadoret & Winokur, 1972). Schizophrenia affects approximately 1% of the population, but the risk is significantly higher for relatives of affected individuals; for instance, siblings of individuals with schizophrenia have about a 10% risk of developing the illness (Dodd, 2007). Similarly, bipolar disorder shows strong familial aggregation, with genetic factors playing a significant role in its transmission (Belmaker, 2004; Tiller & Schweitzer, 2010; Cadoret & Winokur, 1972).

Given these findings, it is widely accepted that schizoaffective disorder also has a strong genetic basis (Marneros, 2012). Family studies indicate that relatives of individuals with schizoaffective disorder have an increased risk of developing not only schizoaffective disorder itself, but also schizophrenia and mood disorders (Maier et al., 1999). This pattern of familial co-aggregation supports the hypothesis that these disorders share common genetic liability factors (Maj & Perris, 1985). The clinical heterogeneity of schizoaffective disorder, particularly the distinction between bipolar and depressive subtypes, may reflect different underlying genetic contributions (Tso et al., 2010; Marneros, 2012). For example, the bipolar subtype of schizoaffective disorder may share more genetic overlap with bipolar I disorder, while the depressive subtype may be more closely related to schizophrenia and major depressive disorder (Maj & Perris, 1985; Marneros, 2012). Some research even suggests that schizoaffective disorder may represent a distinct genetic entity, while other findings place it on a continuum of severity between bipolar disorder and schizophrenia (Ciompi, 1984; Marneros, 2012). The diagnostic uncertainty that often surrounds the disorder, with some clinicians using it for cases with an ambiguous mix of symptoms, further complicates genetic research (Miller et al., 1991).

### Candidate Genes and Molecular Pathways

Research into the specific molecular mechanisms of schizoaffective disorder is in its early stages and is largely guided by findings from schizophrenia and bipolar disorder genetics. The primary molecular targets of psychotropic medications provide crucial clues to the underlying pathophysiology (Janicak, 2014).

**Dopaminergic Pathways:** As discussed previously, the dopamine D2 receptor is the principal target for most antipsychotic drugs (Watanabe, 2007; Zolas & Sher, 2013). This implicates genes involved in the dopamine system—such as those coding for dopamine receptors (D1, D2, D3, D4, D5), transporters, and metabolic enzymes—as potential vulnerability factors for the psychotic symptoms of schizoaffective disorder (Dodd, 2007). Genetic variations that alter dopamine receptor density, sensitivity, or neurotransmitter turnover could contribute to the hyperdopaminergic state thought to underlie psychosis (Juckel & Heinz, 2004; Bressan et al., 2001). For instance, increased D2 receptor density in the striatum has been a finding in schizophrenia research (Dodd, 2007).

**Serotonergic Pathways:** The role of serotonin in mood regulation is well-established, and genes related to the serotonin system are prime candidates for the affective component of schizoaffective disorder (Fiar et al., 2012; Kennedy, 2008). This includes genes for serotonin receptors (e.g., 5-HT1A, 5-HT2A), the serotonin transporter (SERT, the target of SSRIs), and enzymes involved in serotonin synthesis and degradation like tryptophan hydroxylase and monoamine oxidase (MAO) (Scotton et al., 2019; Potter & Goldstein, 2004). Polymorphisms in the serotonin transporter gene, for example, have been linked to vulnerability to depression, particularly in the context of stressful life events (van Praag et al., 2004). The interaction between serotonin and dopamine systems, highlighted by the mechanism of atypical antipsychotics which block both D2 and 5-HT2A receptors, suggests that molecular disruptions in both pathways may be necessary for the full expression of schizoaffective disorder (Janicak, 2014; Gerlach et al., 2014).

**Neurodevelopmental and Neuroplasticity Pathways:** Schizophrenia is increasingly viewed as a neurodevelopmental disorder, with evidence suggesting that genetic and environmental insults in early life disrupt normal brain maturation, leading to the emergence of symptoms in late adolescence or early adulthood (Buckley & Foster, 2014; Fernández-Egea & Jones, 2023). This implicates genes involved in critical neurodevelopmental processes such as neuronal migration, synapse formation, and myelination (Rico, 2012). By extension, these pathways are also relevant to schizoaffective disorder, which shares a similar age of onset and may be preceded by a prodromal phase of declining function (Pereira, 2021; Yung et al., 2006). Molecular mechanisms related to neuroplasticity, synaptic function, and cellular resilience are also central to theories of mood disorders (Anisman et al., 2005). Chronic stress, a major risk factor for depression, is known to impact these processes, potentially through neuroendocrine mechanisms involving the hypothalamic-pituitary-adrenal (HPA) axis (van Praag et al., 2004; Juruena, 2012). Therefore, the molecular basis of schizoaffective disorder likely involves a confluence of genetic variants affecting early brain development, synaptic function, and the capacity of neural circuits to respond and adapt to stress (Ciompi, 1984).

## Brain Structure and Function

The search for the neurological basis of schizoaffective disorder involves examining both the structural architecture and the functional dynamics of the brain. While neuroimaging studies specifically focused on schizoaffective disorder are less numerous than those for schizophrenia and bipolar disorder, the available evidence, combined with inferences from these related conditions, points toward abnormalities in key brain regions and circuits involved in emotion regulation, reality testing, and executive function (Dell’Osso et al., 2012; Juckel & Heinz, 2004).

### Structural Neuroimaging Findings

Structural neuroimaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), have revealed a range of brain abnormalities in patients with severe mental illness (Dell’Osso et al., 2012). In schizophrenia, one of the most consistent findings is ventricular enlargement, particularly of the lateral and third ventricles, which is often accompanied by a reduction in total brain volume and cortical gray matter (Dodd, 2007; Groisman & Seminatore, 2003). Reductions in the volume of specific regions, including the frontal and temporal lobes, hippocampus, and thalamus, have also been frequently reported (Dodd, 2007; Bressan et al., 2001). These structural changes are thought to reflect underlying neurodevelopmental or neurodegenerative processes that contribute to the disorder's symptoms and cognitive deficits (Buckley & Foster, 2014; Rico, 2012).

Studies in bipolar disorder have also identified structural brain changes, though they are often less pronounced than in schizophrenia (Dell’Osso et al., 2012). Findings include increased rates of white matter hyperintensities and some evidence of ventricular enlargement and volume reductions in prefrontal and limbic regions (Dell’Osso et al., 2012). These abnormalities are hypothesized to disrupt the connectivity of circuits responsible for mood regulation (Fiar et al., 2012).

Given its intermediate clinical phenotype, it is hypothesized that schizoaffective disorder may be associated with structural brain abnormalities that are either intermediate between those of schizophrenia and bipolar disorder or represent a combination of findings from both (Marneros, 2012; Maj & Perris, 1985). For example, some studies suggest that patients with schizoaffective disorder show ventricular enlargement and cortical volume reductions that are more severe than in bipolar disorder but less severe than in schizophrenia (Dell’Osso et al., 2012). The heterogeneity of schizoaffective disorder likely contributes to variability in these findings; for instance, the bipolar subtype may show more similarity to bipolar disorder, while the depressive subtype may more closely resemble schizophrenia in its structural brain profile (Marneros, 2012). Abnormalities in limbic structures like the hippocampus and amygdala, which are central to emotion processing and memory, are implicated in both schizophrenia and mood disorders and are therefore highly relevant to the pathophysiology of schizoaffective disorder (Dodd, 2007; Pontius, 1993).

### Functional Neuroimaging and Neural Circuits

Functional neuroimaging studies examine brain activity and connectivity, providing insights into the dynamic processes underlying psychopathology. A prominent finding in schizophrenia is "hypofrontality," or reduced activity in the prefrontal cortex, particularly during tasks that require executive functions like planning, working memory, and attention (Dodd, 2007; Tamminga et al., 1998). This prefrontal dysfunction is thought to be linked to both negative symptoms and cognitive deficits (Tamminga et al., 1998; Arango et al., 2000).

In mood disorders, functional imaging has highlighted dysregulation within a network of brain regions involved in emotion processing and regulation. This network includes the prefrontal cortex, anterior cingulate gyrus, amygdala, and thalamus (Dell’Osso et al., 2012; Fiar et al., 2012). In depression, there is often hyperactivity in limbic and paralimbic areas like the amygdala, coupled with hypoactivity in dorsal prefrontal regions involved in cognitive control (Fiar et al., 2012; Sahakian & Morein‐Zamir, 2011). In mania, a different pattern of dysregulation within this same circuit is observed, often involving heightened activity in ventral prefrontal and limbic structures associated with reward processing and emotional reactivity (Fiar et al., 2012; Swann, 2011).

For schizoaffective disorder, it is plausible that functional abnormalities represent a combination of these patterns. The disorder likely involves dysfunction in the fronto-limbic circuits that regulate mood, leading to depressive or manic episodes, as well as dysfunction in the fronto-striatal and fronto-temporal circuits implicated in the psychotic and cognitive symptoms of schizophrenia (Juckel & Heinz, 2004; Marneros, 2012). Disrupted connectivity between the prefrontal cortex and subcortical structures like the thalamus and basal ganglia may be a common underlying mechanism that gives rise to the diverse symptoms of schizoaffective disorder, from disorganized thought to emotional lability (Dodd, 2007; Dell’Osso et al., 2012). The presence of both psychotic and severe mood symptoms suggests a widespread failure of top-down cognitive and emotional control, originating from prefrontal cortical dysfunction, over subcortical systems responsible for perception, emotion, and motivation (Juckel & Heinz, 2004; Fiar et al., 2012). This model aligns with the clinical presentation of the disorder, where profound disruptions in both thought and affect co-occur and influence one another (Tso et al., 2010).

## Developmental Neurobiology

The emergence of schizoaffective disorder, typically in late adolescence or early adulthood, points to a crucial role for developmental processes in its pathogenesis (Tso et al., 2010; Marneros, 2012). This timing coincides with a period of significant brain maturation, particularly in the prefrontal cortex, and heightened psychosocial stress, suggesting that the disorder arises from an interaction between a pre-existing neurobiological vulnerability and developmental or environmental triggers (Buckley & Foster, 2014; Hechtman, 1991). The neurodevelopmental model, originally proposed for schizophrenia, provides a valuable framework for understanding the onset and early course of schizoaffective disorder (Buckley & Foster, 2014; Rico, 2012).

### Onset and Prodromal Phase

The peak age of onset for schizophrenia is typically in the early to mid-twenties for males and late twenties for females (Buckley & Foster, 2014; Pereira, 2021; Cruz, 2011). Bipolar disorder also commonly begins in late adolescence or early adulthood (Belmaker, 2004; Tiller & Schweitzer, 2010; Krieger & Stringaris, 2013). Schizoaffective disorder shares this typical age of onset, suggesting that common developmental processes are at play (Marneros, 2012; Tso et al., 2010). This period is characterized by ongoing synaptic pruning, myelination, and refinement of neural circuits, particularly those involving the prefrontal cortex and its connections to limbic and temporal regions (Rico, 2012). It is hypothesized that a pre-existing vulnerability, possibly genetic or resulting from early life insults (e.g., perinatal complications), disrupts these final stages of brain maturation, leading to the expression of the illness (Buckley & Foster, 2014; Groisman & Seminatore, 2003).

Many individuals who develop a psychotic disorder experience a prodromal phase, a period of escalating, often non-specific symptoms and functional decline that precedes the first frank psychotic episode (Pereira, 2021; Häfner, 2002; Yung et al., 2006). This phase can last from months to several years (Häfner, 2002; Palma, 2006). Symptoms during the prodrome are often heterogeneous and can include attenuated positive symptoms (e.g., unusual thoughts, perceptual disturbances), negative symptoms (e.g., social withdrawal, apathy), and significant mood and anxiety symptoms (Yung et al., 2006; Schultze‐Lutter, 2016; Benarous, 2016). Depressive symptoms, anxiety, irritability, and sleep disturbances are particularly common in the lead-up to a first psychotic episode (Yung et al., 2006; Pereira, 2021; Benarous, 2016).

This prodromal picture is highly relevant to schizoaffective disorder, as the early phase of the illness often involves a complex mix of affective and sub-threshold psychotic symptoms that can be difficult to distinguish from other conditions like major depression or anxiety disorders (Benarous, 2016; Marneros, 2012). The presence of these early, mixed symptoms supports the idea that the underlying neurodevelopmental disruption affects both mood-regulating and reality-testing circuits from the outset (Kasanin, 1933; Maj & Perris, 1985). Early detection efforts that focus on individuals at "ultra-high risk" (UHR) for psychosis often identify young people with this combination of attenuated psychotic and affective symptoms, highlighting this period as a critical window for potential intervention (Yung et al., 2006; Schultze‐Lutter, 2016).

### Critical Periods and Environmental Factors

The timing of illness onset suggests that adolescence and early adulthood represent a critical period of vulnerability (Buckley & Foster, 2014). During this time, the brain may be particularly susceptible to the effects of environmental stressors, which can interact with an underlying genetic predisposition to trigger the onset of illness (Hechtman, 1991; van Praag et al., 2004). Such stressors can include psychosocial adversity (e.g., trauma, social isolation), academic or occupational pressures, and substance use (Wand, 2008; Hechtman, 1991).

Substance use, particularly cannabis, has been strongly linked to an increased risk of developing a psychotic disorder, especially in genetically vulnerable individuals (Thomas, 1993; Mauri, 2016; Håkansson & Johansson, 2015). The use of psychoactive substances can induce psychotic symptoms directly, precipitate a first episode of a primary psychotic disorder, or worsen the course of an existing illness (Thomas, 1993; Avellaneda Ojeda et al., 2023). Chronic alcohol use and withdrawal can also produce psychosis, delirium, and affective disturbances, further complicating the clinical picture and pointing to shared neurobiological pathways related to CNS hyperexcitability (Saitz, 1998; Stankewicz et al., 2017; Yersin, 1999).

The interaction between these environmental factors and ongoing neurodevelopmental processes is thought to be a key mechanism in the "second hit" model of psychosis (Dodd, 2007). In this model, an early, "first hit" (e.g., genetic risk, perinatal insult) creates a latent vulnerability, which is then unmasked by a "second hit" (e.g., adolescent substance use, psychosocial stress) during the critical period of late brain maturation (Buckley & Foster, 2014). This framework helps explain why schizoaffective disorder, despite its neurodevelopmental roots, typically does not manifest until young adulthood. The interplay of genetic vulnerability, aberrant brain development, and exposure to environmental triggers during a critical window likely culminates in the widespread circuit dysregulation that produces the combined psychotic and affective symptoms of the disorder (Ciompi, 1984; Marneros, 2012).

## Treatment Mechanisms

The pharmacological management of schizoaffective disorder is guided by its dual symptomatology, targeting both psychotic and affective domains (Marneros, 2012). Treatment strategies are often complex, frequently involving polypharmacy with antipsychotics, mood stabilizers, and sometimes antidepressants (Grunze et al., 2009). The biological basis of these interventions lies in their ability to modulate the key neurotransmitter systems implicated in the disorder's pathophysiology (Fiar et al., 2012; Janicak, 2014).

### Antipsychotic Medications

Antipsychotic drugs are the cornerstone of treatment for the psychotic symptoms of schizoaffective disorder, just as they are for schizophrenia (Jibson et al., 2004; Janicak, 2014). Their primary mechanism of action involves the blockade of dopamine D2 receptors in mesolimbic pathways, which is thought to reduce the dopaminergic hyperactivity underlying positive symptoms like delusions and hallucinations (Watanabe, 2007; Janicak, 2014; Zolas & Sher, 2013). This mechanism is effective for acute psychosis regardless of the underlying diagnosis, making antipsychotics useful in schizophrenia, schizoaffective disorder, and the manic phase of bipolar disorder (Battaglia et al., 2007; Janicak, 2014).

Second-generation (atypical) antipsychotics, such as olanzapine, risperidone, quetiapine, and aripiprazole, are often preferred as first-line agents (Janicak, 2014; Gerlach et al., 2014). In addition to D2 antagonism, these agents also typically block serotonin 5-HT2A receptors (Janicak, 2014; Watanabe, 2007). This dual action is hypothesized to offer broader efficacy, potentially improving negative symptoms and cognitive function, and may contribute to mood-stabilizing effects, which are particularly valuable in schizoaffective disorder (Gerlach et al., 2014; Marder, 1996). Aripiprazole has a unique mechanism as a partial agonist at D2 and 5-HT1A receptors, which may offer a favorable balance of efficacy and tolerability (Rodríguez, 2008; Rapagnani, 2012). The choice of antipsychotic is often guided by the side effect profile, as these agents are associated with risks of extrapyramidal symptoms (more common with first-generation agents) and metabolic side effects like weight gain and diabetes (more common with some second-generation agents) (Möller, 2004; Rikhari & Kumar, 2021). Long-acting injectable formulations are an important option to ensure adherence in this chronic illness (Shah et al., 2018).

### Mood-Stabilizing Agents

For the management of the bipolar type of schizoaffective disorder, and for manic symptoms in general, mood stabilizers are essential (Marneros, 2012; Goikolea, 2008). Lithium salts have long been the gold standard for treating and preventing manic episodes in bipolar disorder (Belmaker, 2004; Thomas, 2003). While its precise mechanism is not fully understood, lithium is known to modulate intracellular signaling pathways, including second messenger systems, which influences neurotransmission and neuroplasticity (Kahn & Chaplan, 2002; Fiar et al., 2012).

Anticonvulsant medications, such as valproate and carbamazepine, are also widely used as mood stabilizers (Belmaker, 2004; Thomas, 2003). Their mechanisms are thought to involve the enhancement of GABAergic inhibition and modulation of voltage-gated ion channels, which reduces neuronal excitability (Löscher, 2009). This action may be particularly relevant for controlling the hyperexcitable state of mania (Thomas, 2003; Mir et al., 2022). Lamotrigine, another anticonvulsant, has shown particular efficacy in preventing depressive episodes in bipolar disorder (Belmaker, 2007; Thase, 2005). In schizoaffective disorder, bipolar type, these mood stabilizers are often combined with an antipsychotic to provide comprehensive control of both manic and psychotic symptoms (Grunze et al., 2009; Marneros, 2012).

### Antidepressant Medications

The use of antidepressants in schizoaffective disorder, depressive type, and during depressive episodes of the bipolar type is more complex and controversial (Felmet et al., 2010; Marneros, 2012). While antidepressants, particularly SSRIs like fluoxetine and sertraline, are effective for major depressive disorder by increasing synaptic serotonin, their use in patients with a history of psychosis or mania carries risks (Bains et al., 2021; Montgomery et al., 1993). A primary concern is the potential for antidepressant monotherapy to induce a switch into mania or hypomania or to cause mood destabilization and rapid cycling in vulnerable individuals (Swann, 2009; Keck et al., 2007; Kora & Kaplan, 2008; Kalla, 2020).

Therefore, current guidelines generally recommend that if an antidepressant is used for a depressive episode in schizoaffective disorder, bipolar type, it should be co-prescribed with a mood stabilizer or an atypical antipsychotic with mood-stabilizing properties (Keck et al., 2007; Thase, 2005). For the depressive type of schizoaffective disorder, the combination of an antipsychotic and an antidepressant is a common strategy (Felmet et al., 2010). Some atypical antipsychotics, such as quetiapine and lurasidone, have demonstrated efficacy for bipolar depression as monotherapy, suggesting they may possess intrinsic antidepressant properties, possibly through actions on serotonin and norepinephrine receptors (Belmaker, 2007; Cruz, 2011). This highlights the intricate neuropharmacology required to treat a disorder that simultaneously affects multiple dimensions of psychopathology (Marneros, 2012).

## Future Directions

Despite its recognition as a distinct clinical entity for nearly a century (Kasanin, 1933), schizoaffective disorder remains one of the least understood major psychiatric illnesses from a biological standpoint (Tso et al., 2010; Miller et al., 1991). The future of research in this area must focus on elucidating the specific neurobiological mechanisms that distinguish it from, and link it to, schizophrenia and mood disorders. This endeavor is critical for refining diagnostic criteria, developing targeted treatments, and improving long-term outcomes for a patient population that often experiences significant disability (Wright & Burns, 2002).

A primary challenge and a crucial direction for future research is the biological validation of schizoaffective disorder as a discrete category versus a point on a psychosis-affective continuum (Marneros, 2012; Ciompi, 1984). Large-scale longitudinal studies incorporating genetic, neuroimaging, and neurophysiological measures are needed. Such studies should compare well-defined cohorts of patients with schizoaffective disorder (both bipolar and depressive subtypes), schizophrenia, and bipolar disorder over time (Maj & Perris, 1985). This approach could help identify unique biomarkers or endophenotypes for schizoaffective disorder, or alternatively, confirm that its biological profile is truly intermediate between the other two disorders (Marneros, 2012). Understanding the genetic architecture is paramount; future genomic studies must move beyond candidate gene approaches to genome-wide association studies (GWAS) and whole-genome sequencing specifically in schizoaffective cohorts to identify risk loci that may be unique to the disorder or represent specific combinations of risk alleles for psychosis and mood dysregulation (Maier et al., 1999).

The heterogeneity within schizoaffective disorder itself warrants deeper investigation. The distinction between the bipolar and depressive subtypes is clinically fundamental, and future research must explore whether these subtypes have distinct neurobiological underpinnings (Tso et al., 2010; Maj & Perris, 1985). For instance, do they differ in terms of brain structure, functional connectivity in mood-regulating circuits, or response to specific pharmacological agents? Comparing the biology of schizoaffective disorder, depressive type, with that of schizophrenia with prominent depressive symptoms could help clarify the boundary between these conditions (Felmet et al., 2010; Martin et al., 1985). Similarly, comparing the bipolar subtype to bipolar I disorder with psychotic features is essential for refining diagnostic boundaries (Steffens et al., 2013; Miller et al., 1991).

Advances in neuroimaging offer powerful tools to probe the neural circuitry of schizoaffective disorder. Future studies should employ multimodal imaging (e.g., combining structural MRI, functional MRI, and PET) to investigate the integrity and function of fronto-limbic, fronto-striatal, and fronto-temporal networks (Dell’Osso et al., 2012). Investigating how functional connectivity within these networks changes across different mood states (manic, depressed, euthymic) within the same schizoaffective individuals could provide critical insights into the state-dependent and trait-like neural dysfunctions of the disorder. This could clarify whether the co-occurrence of symptoms is due to a shared, underlying circuit deficit or the interaction of distinct pathological processes (Juckel & Heinz, 2004).

From a therapeutic perspective, the future lies in developing treatments that are specifically tailored to the neurobiology of schizoaffective disorder. Current strategies largely borrow from the treatment of schizophrenia and bipolar disorder, often resulting in complex polypharmacy (Grunze et al., 2009). A better understanding of the specific neurotransmitter imbalances could lead to novel pharmacological targets. For example, if specific glutamatergic or GABAergic dysfunctions are confirmed to be central to the disorder, this could spur the development of agents that modulate these systems more selectively than current anticonvulsant mood stabilizers (Löscher, 2009). Furthermore, identifying biological predictors of treatment response is a critical goal. Genetic markers, baseline neuroimaging profiles, or neurophysiological measures could potentially guide clinicians in selecting the most effective combination of antipsychotic and mood-stabilizing agents for an individual patient, moving the field toward a more personalized medicine approach (Janicak, 2014). Finally, the role of comorbid conditions, especially substance use disorders, needs to be integrated into biological research, as substance use can profoundly alter brain function and clinical presentation, confounding the search for primary pathophysiological mechanisms (Thomas, 1993; Weaver et al., 2024; San et al., 2004).

## Conclusion

Schizoaffective disorder stands at the crossroads of psychosis and mood disturbance, presenting a formidable challenge to clinicians and neuroscientists alike (Tso et al., 2010; Kasanin, 1933). Its biological basis remains an area of intensive inquiry, with current understanding largely synthesized from the more extensively studied fields of schizophrenia and bipolar disorder (Marneros, 2012; Maj & Perris, 1985). The evidence reviewed in this chapter points toward a complex, multifactorial pathophysiology involving genetic vulnerabilities and dysregulation across several key neurobiological systems.

The psychotic dimension of the illness, characterized by delusions and hallucinations, strongly implicates dysfunction in dopaminergic pathways, a conclusion supported by the efficacy of D2-receptor-blocking antipsychotic medications (Janicak, 2014; Buckley & Foster, 2014). Simultaneously, the profound affective instability—manifesting as either manic or depressive episodes—points to the involvement of serotonergic and noradrenergic systems, which are the primary targets of mood-stabilizing and antidepressant drugs (Fiar et al., 2012; Belmaker, 2004). The unique clinical presentation of schizoaffective disorder likely arises from a complex and dynamic interplay between these neurotransmitter systems, possibly compounded by a fundamental imbalance in cortical excitatory-inhibitory tone mediated by glutamate and GABA (Löscher, 2009).

Structurally and functionally, the disorder appears to affect the critical neural circuits that bridge the prefrontal cortex with limbic and striatal regions. These networks are essential for the integration of cognition, emotion, and perception (Dell’Osso et al., 2012). Disrupted connectivity within this circuitry could provide a unifying neurobiological framework for how deficits in reality testing and emotional regulation can co-occur and influence one another. The typical onset of the disorder in late adolescence or early adulthood underscores a neurodevelopmental component, suggesting that a pre-existing vulnerability interacts with maturational processes and environmental stressors during a critical period to precipitate the full-blown illness (Buckley & Foster, 2014; Yung et al., 2006).

While our current treatment paradigm relies on combining agents developed for schizophrenia and bipolar disorder, the ultimate goal is to develop therapies based on the specific neurobiology of schizoaffective disorder itself (Marneros, 2012). Achieving this will require dedicated research that embraces the disorder's heterogeneity, seeking to identify biomarkers that can differentiate its subtypes and predict treatment outcomes. By continuing to unravel the intricate genetic, molecular, and circuit-level mechanisms, future research holds the promise of moving beyond a syndromal understanding to a truly neurobiological conceptualization of schizoaffective disorder, paving the way for more precise diagnostics and more effective, personalized interventions.

## References

1. Abad, A., Matesanz, C. M., Acosta, C. R. D., & López, C. M. (2022). Sleep apnoea and sleep disorders. Pathy's Principles and Practice of Geriatric Medicine. https://doi.org/10.1002/9781119484288.ch45
2. Abi‐Jaoude, E., Stall, N. M., & Rochon, P. A. (2018). Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.181486
3. Adams, C. E., Wilson, P., Gilbody, S., Bagnall, A., & Lewis, R. (2000). Drug treatments for schizophrenia. Quality in Health Care. https://doi.org/10.1136/qhc.9.1.73
4. Adetunji, B., Matthews, M., Basil, B., & Oyemade, A. (2007). "Bipolar Family". The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0211e
5. Agarwal, K., Yadav, A. K., Verma, P., & Kaur, B. (2021). DYSTHYMIA AND it’s HOMOEOPATHIC MANAGEMENT. Journal of Emerging Technologies and Innovative Research.
6. Agudelo, D., Spielberger, C. D., & Buela‐Casal, G. (2007). La depresión: ¿un trastorno dimensional o categorial?. Salud Mental.
7. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
8. Aihara, M. (2012). Epilepsy with Continuous Spike-Waves during Slow Sleep: When and How Should We Treat?. Pediatrics & Therapeutics. https://doi.org/10.4172/2161-0665.1000e113
9. Ajayi, O., Esangbedo, A., Lawal, A. A., Olanrewaju, A. O., Ojo, T. O., & Talabi, O. (2023). Moral Injury, Trance and Possession State or a Schizophrenic Illness. a Case report. BJPsych Open. https://doi.org/10.1192/bjo.2023.359
10. Ajiboye, P., & Yusuf, A. D. (2013). Scientific Letter: Monosymptomatic Hypochondriacal Psychosis (somatic delusional disorder): A report of two cases. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v16i2.11
11. Al-Balawi, T., Al-Greeshah, F., & Khan, S. (2003). Management of status epilepticus.. PubMed.
12. Albano, A. M., & Silverman, W. K. (2024). Bipolar Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348367.003.0017
13. Albano, A. M., & Silverman, W. K. (2024). Bipolar Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348381.003.0016
14. Albano, A. M., & Silverman, W. K. (2024). Disruptive Mood Dysregulation Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348367.003.0016
15. Albano, A. M., & Silverman, W. K. (2024). Major Depressive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348367.003.0014
16. Albano, A. M., & Silverman, W. K. (2024). Obsessive-Compulsive Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348367.003.0012
17. Albano, A. M., & Silverman, W. K. (2024). Panic Disorder. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348381.003.0010
18. Albano, A. M., & Silverman, W. K. (2024). Tic Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780199348381.003.0019
19. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
20. Alfarossi, O. L., & Hutasoit, H. B. K. (2020). Gejala Psikotik pada Pasien dengan Epilepsi Tidak Terkontrol. Jurnal Medula.
21. Alvarez, M. R., García, R. G., & Silva, F. A. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas. Acta neurológica colombiana.
22. Ananto, A. S., & Suryati, E. (2019). Ensefalopati Hipertensi pada Anak dengan Glomerulonefritis Akut Pasca Streptokokal.
23. Andreev, A. (2000). [Differentiated types of chronic agoraphobia].. PubMed.
24. Andresen, M., & Andresen-Vasquez, M. (2016). A new instrument for assessing the experience of dying and death in the intensive care units from the perspective of relatives. Journal of Thoracic Disease. https://doi.org/10.21037/jtd.2016.06.07
25. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
26. Antoniuk, S. A. (2013). [Non-epileptic disorders in infancy and adolescence].. PubMed.
27. Anuzyte, J. S., Rutkauskaitė, G., & Mameniškienė, R. (2018). Transient epileptic amnesia. Neurologijos seminarai. https://doi.org/10.29014/ns.2018.26
28. Aponte-Puerto, A., Rozo-Osorio, J. D., Guzman-Porras, J. J., Patiño-Moncayo, A. D., Amortegui-Beltrán, J. A., & Uscátegui-Daccarett, A. M. (2018). Febrile Infection-Related Epilepsy Syndrome (FIRES), a possible cause of super-refractory status epilepticus. Case report.. Case reports. https://doi.org/10.15446/cr.v4n1.61288
29. Arain, S., Shakhori, M. A., Thorakkattil, S. A., & Amin, O. (2023). Acute Psychotic Episode Induced by Antimicrobial Treatment. Case Reports in Psychiatry. https://doi.org/10.1155/2023/9996763
30. Arandjelovic, D., Misic, P., Serafimovic, S., & Petrovic, M. (2010). P01-366 - Psychiatric Syndromes and Disorders in Older Population. European Psychiatry. https://doi.org/10.1016/s0924-9338(10)70574-5
31. Arango, C., Kirkpatrick, B., & Buchanan, R. W. (2000). Neurological Signs and the Heterogeneity of Schizophrenia. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.157.4.560
32. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
33. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2013). Nonconvulsive status epilepticus and psychotic symptoms: case report.. PubMed. https://doi.org/10.1708/1292.14295
34. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
35. Artto, V., & Kallela, M. (2012). [Treatment of prolonged migraine attack (status migrenosus)].. PubMed.
36. As, B., On, C., & NIu, R. (2014). [Bipolar depression in the clinic of schizophrenia].. PubMed.
37. Avari, J., Yuen, G. S., AbdelMalak, B., Mahgoub, N., Kalayam, B., & Alexopoulos, G. S. (2014). Assessment and Management of Late-Life Depression. Psychiatric Annals. https://doi.org/10.3928/00485713-20140306-04
38. Bach, S. (2018). States of consciousness. Routledge eBooks. https://doi.org/10.4324/9780429471391-3
39. Bailey, K. S., & Dewey, C. W. (2009). The Seizuring Cat. Journal of Feline Medicine and Surgery. https://doi.org/10.1016/j.jfms.2009.03.006
40. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
41. Baldwin, D. S. (2007). Abstracts from the 7th international forum on mood and anxiety disorders. International Journal of Psychiatry in Clinical Practice. https://doi.org/10.1080/13651500701745584
42. Balhara, Y. P. S., Mohan, I., Sagar, R., & Chawla, J. (2006). Chronic mania: An unexpectidly long episode?. Indian Journal of Medical Sciences. https://doi.org/10.4103/0019-5359.25681
43. Ballon, J. S., & Lieberman, J. A. (2010). Advances in the Management of Treatment- Resistant Schizophrenia. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/foc.8.4.foc475
44. Banazak, D. A. (2000). Minor depression in primary care.. PubMed.
45. Bansal, R., & Sheldon, S. H. (2008). Parasomnias in Childhood. CRC Press eBooks. https://doi.org/10.3109/9781420048087-26
46. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
47. Barnes, T. R. E., & Paton, C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. https://doi.org/10.1136/bmj.d3371
48. Barolin, G. S. (1998). Rehabilitation hospitalism. International Journal of Rehabilitation Research. https://doi.org/10.1097/00004356-199806000-00008
49. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
50. Battaglia, J., Robinson, D. G., & Citrome, L. (2007). The Treatment of Acute Agitation in Schizophrenia. CNS Spectrums. https://doi.org/10.1017/s1092852900026146
51. Baumgärtner, J., Fellinger, M., Grüner, C., Friedrich, F., & Mossaheb, N. (2018). Bipolare affektive Psychose als Komorbidität einer Autismus-Spektrum-Störung. psychopraxis neuropraxis. https://doi.org/10.1007/s00739-018-0451-9
52. Bayarri, P. G., Márquez, L. R., Chilet, R. C., Cano, N., Sanbartolomé, A. R. I., Torrella, M. E., & Plaza, G. Z. (2011). Patología del sueño en paciente con patología psiquiátrica. Aportes de la Neurofisiología.. Psiquiatria.com.
53. Bayliss, E. A., Shetterly, S., Drace, M. L., Norton, J. D., Maiyani, M., Gleason, K., Sawyer, J. K., Weffald, L. A., Green, A. R., Reeve, E., Maciejewski, M. L., Sheehan, O. C., Wolff, J. L., Kraus, C. R., & Boyd, C. M. (2022). Deprescribing Education vs Usual Care for Patients With Cognitive Impairment and Primary Care Clinicians. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.0502
54. Bazan, L., Roth, T., & Drake, C. L. (2011). Management of Insomnia. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-735-8_14
55. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
56. Becker, M. A., Weinberger, T. E., & Ocker, L. J. (2022). Mood Disorders. CRC Press eBooks. https://doi.org/10.1201/9781003099062-21
57. Beghi, E., & Hauser, W. A. (2008). First seizure definitions and worldwide incidence and mortality. Epilepsia. https://doi.org/10.1111/j.1528-1167.2008.01443.x
58. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
59. Bell, C. M. (2009). L. https://doi.org/10.1093/oso/9780195341591.003.0012
60. Belli, H., Akbudak, M., Ural, C., & Kulacaoğlu, F. (2012). Solitary lesion in ponto-mesencephalic area related secondary mania: a case report.. PubMed.
61. Belmaker, R. H. (2004). Bipolar Disorder. New England Journal of Medicine. https://doi.org/10.1056/nejmra035354
62. Belmaker, R. H. (2007). Treatment of Bipolar Depression. New England Journal of Medicine. https://doi.org/10.1056/nejme078042
63. Benarous, X. (2016). Affective symptoms and emerging psychotic disorder in adolescents. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2016.01.1217
64. Bentes, C., & Pimentel, J. G. (2012). Estado de mal convulsivo. Aspectos fisiopatológicos e clínicos.. Acta Médica Portuguesa. https://doi.org/10.20344/amp.1154
65. Benítez, M. S. H., Castresana, C. D. L. C., Revuelta, J. L. G. D. R. Y., & Marco, R. G. (1991). Relevancia de factores psicosociales en el aparato respiratorio. Psiquis: Revista de psiquiatría, psicología médica y psicosomática.
66. Bermúdez, C. M., & Barrientos, M. P. S. (2011). Manejo Integral de un paciente con secuelas neuropsiquiátricas por consumo crónico de alcohol. REVISTA MÉDICAS UIS.
67. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
68. Bezerra, E. D. L., & Zimmermann, M. (2015). DISTÚRBIOS COMPORTAMENTAIS EM CÃES: Ansiedade por Separação.
69. Bhat, P., Ryali, V., Srivastava, K., Kumar, S., Prakash, J., & Singal, A. (2012). Alcoholic hallucinosis. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.119646
70. Biederman, J., Rivinus, T. M., Kemper, K. J., Hamilton, D., MacFadyen, J., & Harmatz, J. S. (1985). Depressive disorders in relatives of anorexia nervosa patients with and without a current episode of nonbipolar major depression. American Journal of Psychiatry. https://doi.org/10.1176/ajp.142.12.1495
71. Bienvenu, O. J. (2014). Depressive Mood States Following Critical Illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199653461.003.0020
72. Bjorvatn, B., Jernelöv, S., & Pallesen, S. (2021). Insomnia – A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.639198
73. Blay, S. L. (2011). A Case of Major Depressive Disorder and Symptoms of Polycystic Ovary Syndrome Responding to Escitalopram. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01183
74. Bloom, B. L. (2004). The Implications Of Controlled Outcome Studies On Planned Short-Term Psychotherapy With Depressive Disorders. https://doi.org/10.1093/oso/9780195165005.003.0029
75. Blumenthal, J. A., & Lett, H. S. (2005). Depression and Cardiac Risk. Journal of Cardiopulmonary Rehabilitation. https://doi.org/10.1097/00008483-200503000-00005
76. Bosisio, A. C. M. (2004). Acute Confusional State. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508434.003.0022
77. Bostankolu, G., Ayhan, Y., Çetin, F. Ç., & Yazıcı, M. K. (2014). Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125314561467
78. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
79. Braksick, S. A., & Wijdicks, E. F. M. (2019). Neurogenic Cardiac Manifestations. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0017
80. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
81. Braun-Scharm, H. (1991). [Obsessive phenomena in schizophrenic adolescents].. PubMed.
82. Bresaly, R., Albokhari, A., Mal, R., Tashkandi, A., Alsawas, A., Abualshamat, M., Harazi, G. A., Alamri, S., Shabekni, A., Alharthi, A. A. M., Alwadai, M., Alluqmani, M., Alsabban, A., Hamza, A. A., & Aladalah, A. S. (2022). Suicidal Attempt in a Schizophrenic Patient with a High Level of Expressed Emotion. International Journal Of Pharmaceutical Research And Allied Sciences. https://doi.org/10.51847/7geaqz0z0k
83. Bressan, R. A., Bigliani, V., & Pilowsky, L. S. (2001). Neuroimagem de receptores D2 de dopamina na esquizofrenia. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462001000500014
84. Briley, M. (2011). Noradrenergic symptom cluster in depression. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s19611
85. Brim, J., Wetzel, R. D., Reich, T., Wood, D. D., Viesselman, J. O., & Rutt, C. (1984). Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms.. PubMed.
86. Brink, S. (2004). CPD Article: New therapies in schizophrenia.. South African Family Practice.
87. Brinkmann, B. H. (2021). Mental Disorder Issues in People.
88. Bromberger, J. T. (1998). Gender and Depression. https://doi.org/10.1093/oso/9780195113969.003.0003
89. Brown, H. E., Stoklosa, J., & Freudenreich, O. (2012). How to Stabilize an Acutely Psychotic Patient: In Psychiatric Emergencies, Use a Stepwise Approach to Provide Safe, Effective Treatment. Current psychiatry.
90. Brusgaard, K., Møller, R. S., Dahl, H. A., & Hjalgrim, H. (2011). Graduated clinical manifestations according to mutation type in patients with severe myoclonic epilepsy in infancy. Research Portal Denmark.
91. Brust, J. C. (2002). Seizures and Illicit Drug Use. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-094-0_11
92. Buchwald, A. M., & Rudick-Davis, D. (1993). The symptoms of major depression.. Journal of Abnormal Psychology. https://doi.org/10.1037//0021-843x.102.2.197
93. Buckey, J. C. (2006). Psychosocial Support: Maintaining an Effective Team. https://doi.org/10.1093/oso/9780195137255.003.0002
94. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
95. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
96. Burke, A., Yaari, R., Tariot, P. N., Dougherty, J., Fleisher, A., & Brand, H. (2012). The Shadow People. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12alz01398
97. Busse, J. W. (2007). The Neuroendocrinology of Medically Unexplained Syndromes. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-008-9_23
98. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le trouble hyperkinétique ou déficit de l'attention/hyperactivité. Le point sur... Psychologie.
99. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
100. Cadoret, R. J., & Winokur, G. (1972). Genetic Principles in the Classification of Affective Illnesses. International Journal of Mental Health. https://doi.org/10.1080/00207411.1972.11448572
101. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Post-Stroke Apathy: An Exploratory Longitudinal Study. Cerebrovascular Diseases. https://doi.org/10.1159/000350202
102. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Supplementary Material for: Post-Stroke Apathy: An Exploratory Longitudinal Study. Figshare. https://doi.org/10.6084/m9.figshare.5124829
103. Calabrese, P. (2021). Impact of Mental Disorder in Human Being.
104. Cambra, P. R. (2021). Trastorno mental grave, pacientes con esquizofrenia.. Revista Sanitaria de Investigación.
105. Campoy, A. T., Rotger, M. Y., Gutiérrez, L. R. D. L. H., González, S. M. B., & Pastorelli, R. V. (2011). Dificultad diagnóstica de los trastornos de personalidad. A propósito de un caso.. Psicologia.com.
106. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
107. CASEY, P., & Bailey, S. (2011). Adjustment disorders: the state of the art. World Psychiatry. https://doi.org/10.1002/j.2051-5545.2011.tb00003.x
108. Chandra, D., Raj, K. S., & Prema (2018). Obstructive Sleep Apnea and Its Prosthodontic Management- An Overview. International Journal of Health Sciences and Research.
109. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
110. Charil, A., & Inglese, M. (2012). Predicting short-term conversion from CIS to MS. Neurology. https://doi.org/10.1212/wnl.0b013e31827dec22
111. Charmaz, K. (2007). Chronic Illness and Disability. The Blackwell Encyclopedia of Sociology. https://doi.org/10.1002/9781405165518.wbeosc035
112. Chiliza, B., & Vythilingum, B. (2011). Consultation liaison psychiatry in Africa – essential service or unaffordable luxury?. African Journal of Psychiatry. https://doi.org/10.4314/ajpsy.v14i4.1
113. Choo, K.-Q., Wl, L., How, C., & Ng, B. (2015). Hoarding in Singapore. Singapore Medical Journal. https://doi.org/10.11622/smedj.2015131
114. Chou, C. J. (2009). Mixed Episodes with Psychotic Features. CNS Spectrums. https://doi.org/10.1017/s1092852900003886
115. Ciompi, L. (1984). Is there really a Schizophrenia? The Long-term Course of Psychotic Phenomena∗. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.145.6.636
116. Citrome, L. (2015). A primer on binge eating disorder diagnosis and management. CNS Spectrums. https://doi.org/10.1017/s1092852915000772
117. Clavé, P., Terré, R., Kraa, M. D., & Serra, M. (2004). Approaching oropharyngeal dysphagia. Revista Española de Enfermedades Digestivas. https://doi.org/10.4321/s1130-01082004000200005
118. Coghill, D., Bonnar, S., Duke, S., Graham, J., & Seth, S. (2009). Obsessive compulsive disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199234998.003.0020
119. Conde, B. U. (2016). Trastorno de la conducta alimentaria, trastorno por déficit de atención e hiperactividad, e impulsividad: un estudio sobre su relación.
120. Conway, K. P., Montoya, I. D., & Compton, W. M. (2007). Lifetime Psychiatric Comorbidity of Illicit Drug Use Disorders. The Psychiatric times.
121. Coppen, A., & Swade, C. (1988). 5-HT and Depression: the Present Position. https://doi.org/10.1007/978-1-349-09506-3_9
122. Cottencin, O., Danel, T., Goudemand, M., Thomas, P., & Consoli, S. M. (2009). Catatonia recognition and treatment.. PubMed.
123. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
124. Cruz, M. P. (2011). Lurasidone HCl (Latuda), an Oral, Once-Daily Atypical Antipsychotic Agent for the Treatment of Patients with Schizophrenia.. PubMed.
125. D'Agati, S., Teodoro, M. C., Tomaselli, T., Barbera, N., D’Agati, A., & Zarbo, G. (2011). Depressione post-partum: valutazione clinica e medico-legale.
126. Dafotakis, M. (2012). Psychogene Bewegungsstörungen - Klinische Präsentation. Klinische Neurophysiologie. https://doi.org/10.1055/s-0032-1301499
127. Daley, D. C., & Douaihy, A. (2006). The Recovery Process for Addiction and Mood Disorders. https://doi.org/10.1093/oso/9780195311297.003.0004
128. Daley, D. C., & Douaihy, A. (2006). Understanding Mood Disorders: Depression and Bipolar Illness. https://doi.org/10.1093/oso/9780195311297.003.0003
129. Daudin, M., & Rondier, J. (2014). Traumatisme de guerre, conduites addictives : une illustration du concept lacanien de jouissance. L information psychiatrique. https://doi.org/10.1684/ipe.2014.1223
130. Davies, S., & Heyman, I. (2004). Psychiatric aspects. CRC Press eBooks. https://doi.org/10.1201/b13560-60
131. Dedeli, Ö., & Akyol, A. D. (2005). Yoğun Bakım Sendromu. Yoğun Bakım Hemşireliği Dergisi.
132. Demir, C. F., Hasan, H., & Cura, H. S. (2013). Absence status seen in an adult patient. Journal of Neurosciences in Rural Practice. https://doi.org/10.4103/0976-3147.118809
133. Demuynck, E. M. (2016). Le syndrome de Sharp et les troubles psychiatriques en psychiatrie de liaison : à propos d’une observation. L information psychiatrique. https://doi.org/10.1684/ipe.2016.1568
134. Demuynck, E. M. (2016). Sharp's syndrome and psychiatric disorders in liaison psychiatry: Concerning an observation. L information psychiatrique.
135. Demuynck, E. M. (2016). Sharp’s syndrome and psychiatric disorders in liaison psychiatry: An observation. L information psychiatrique.
136. Denysenko, M. (2018). ДІАГНОСТИЧНІ КРИТЕРІЇ НЕВРАСТЕНІЇ З ПІДВИЩЕНИМ РИЗИКОМ АДИКТИВНОЇ ПОВЕДІНКИ. Вісник соціальної гігієни та організації охорони здоров я України. https://doi.org/10.11603/1681-2786.2017.3.8270
137. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
138. Derouesné, C. (2006). Démence à corps de Lewy : nouveau consensus. Gériatrie et Psychologie Neuropsychiatrie du Viellissement.
139. Devi, D. K. S. (2013). Study of the Differences in the Quality of Life and Disability among Patients with Schizophrenia and Bipolar Disorders and Assessment of the Burden among their Care Givers..
140. Dexter, M., & Aggarwal, A. (2018). Medical, pharmacological and neurosurgical perspectives on trigeminal neuralgia. Australian Endodontic Journal. https://doi.org/10.1111/aej.12255
141. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
142. Dilsaver, S. C., Halle, M. H., & Medico, V. J. D. (1991). Symptoms of major depression: acute effect of withdrawing antidepressants. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1991.tb05531.x
143. Dobrea, C., Dell’Osso, B., Carlotta, M., Cremaschi, L., Arici, C., Benatti, B., & Carlo, A. D. (2012). Neuroimaging Data in Bipolar Disorder: An Updated View. InTech eBooks. https://doi.org/10.5772/24566
144. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
145. Dodick, D. W., & Roarke, M. C. (2007). Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00889.x
146. Donghi, A. (2005). ALCANCE DE LA APLICACIÓN DEL MODELO DE REDUCCIÓN DE DAÑOS AL CAMPO ASISTENCIAL EN EL TRATAMIENTO DE LAS ADICCIONES. XII Jornadas de Investigación y Primer Encuentro de Investigadores en Psicología del Mercosur.
147. Douglas, M. E., Kim, B., Mayer, G., Crosby, B., & Towe-Goodm, N. (2012). Maternal Depression, Mothering and Child Development. InTech eBooks. https://doi.org/10.5772/38048
148. Downar, J., Blumberger, D. M., & Daskalakis, Z. J. (2016). Repetitive transcranial magnetic stimulation: an emerging treatment for medication-resistant depression. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.151316
149. Doğru, H. Y., Özsoy, A. Z., İşgüder, Ç. K., Özsoy, F., Delibaş, İ. B., & Çakmak, B. (2015). Gebelikte Tekrar Eden İntihar Girişimlerine Rağmen Fatal Seyretmeyen O sesif- Kompulsif Bozukluk:Olgu Sunumu. Gaziosmanpaşa Üniversitesi Tıp Fakültesi Dergisi.
150. Dreyer-Oren, S. E., Mitnaul, L., & Holtzheimer, P. E. (2018). Mood Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615372423.sy25
151. Dudek, D., & Sobański, J. A. (2012). Mental disorders in somatic diseases: psychopathology and treatment. Polskie Archiwum Medycyny Wewnętrznej. https://doi.org/10.20452/pamw.1539
152. Duntley, S. P. (2004). Sleep State Misperception. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-662-1_8
153. Duntley, S. P. (2011). Insomnia: Acute and Emergent Aspects. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195377835.003.0004
154. Duval, F., Jautz-Duval, M. M., González, F., & Rabia, H. (2010). Bases neurobiológicas de vulnerabilidad psiquiátrica a lo largo de las etapas de la vida hormonal de la mujer. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272010000500005
155. Economou, N.-T., Manconi, M., Ghika, J., Raimondi, M., & Bassetti, C. L. (2011). Development of Parkinson and Alzheimer Diseases in Two Cases of Narcolepsy-Cataplexy. European Neurology. https://doi.org/10.1159/000334733
156. Edwards, G., Marshall, E. J., & Cook, C. C. H. (2003). Withdrawal states and treatment of withdrawal. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511543722.018
157. Enrique, P. M. L., Gloria, A. S., Efraín, S. C. J., & Luis, G. A. J. (2019). Latencia diagnóstica en la enfermedad de Parkinson y su relación con los síntomas prodrómicos motores y no motores. eNeurobiología.
158. Escribano, S. A. (2018). Estudio de la eficacia de un tratamiento psicológico breve en la disminución de la sensibilidad a la ansiedad en pacientes con trastorno de pánico.
159. Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2006). Trastorno perceptivo persistente por alucinógenos después del consumo de psilocibina: un estudio clínico. European psychiatry (Ed Española). https://doi.org/10.1017/s1134066500003738
160. Evren, C., & Dalbudak, E. (2009). Relationship of Personality Trait Impulsivity with Clinical Variables in Male Alcohol-Dependent Inpatients. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
161. Ezzaher, A., Haj, D., Mechri, A., Neffati, F., Douki, W., Gaha, L., & Fadhel, M. (2012). Cardiovascular Risk in Tunisian Patients with Bipolar I Disorder. InTech eBooks. https://doi.org/10.5772/30353
162. Faber, J., Vladyka, Dufková, D., Faltus, F., Jirák, R., Pavlovský, P., Smídová, E., Zvolský, P., Žukov, I., Klár, I., Posmurová, M., & Srutová, L. (1996). "Epileptosis"--a syndrome or useless speculation?. PubMed.
163. Faravelli, C., Zucchi, T., Perone, A., Salmoria, R., & Viviani, B. (2001). Social Phobia. https://doi.org/10.1002/0470846437.ch7
164. Fava, G. A., Ruini, C., & Sonino, N. (2002). Management of Recurrent Depression in Primary Care. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000067189
165. Fazel, M., Reed, R. V., & Goldring, L. (2012). Post-traumatic stress disorder. BMJ. https://doi.org/10.1136/bmj.e3790
166. Felmet, K., Zisook, S., & Kasckow, J. (2010). Elderly Patients with Schizophrenia and Depression: Diagnosis and Treatment. Clinical Schizophrenia & Related Psychoses. https://doi.org/10.3371/csrp.4.4.4
167. Feng, G. (2008). Relationship Study between Chronic Fatigue Syndrome and Emotional Factors. Liaoning Zhongyiyao Daxue xuebao.
168. Fenichel, G. M. (2022). Altered States of Consciousness. WORLD SCIENTIFIC eBooks. https://doi.org/10.1142/9789811260735_0011
169. Fernández-Egea, E., & Jones, P. B. (2023). Schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/9781911623137.065
170. Fiar, Z., Hroudov, J., & Raboch, J. (2012). Neurotransmission in Mood Disorders. InTech eBooks. https://doi.org/10.5772/31831
171. Flügel, D. (2012). Psychosis and Epilepsy. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199796793.003.0024
172. Fond, G., Jollant, F., & Abbar, M. (2010). The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome). International Psychogeriatrics. https://doi.org/10.1017/s1041610210001663
173. Forbes, F. (2010). Improving recognition and management of ADHD.. Practitioner.
174. Foroutan, H. R., Vadiee, I., Nabavizadeh, A., Rafiee, M., Imanieh, M. H., Asadipouya, A., & Pirastehfar, M. (2005). CIDP and Achalasia: Two manifestations of a Disease or Coincidental Association. Iranian journal of medical sciences.
175. Forrest, J., Willis, L., Holm, K., Kwon, M. S., Anderson, M. A., & Foreman, M. D. (2007). Recognizing quiet delirium.. PubMed. https://doi.org/10.1097/01.naj.0000265267.77070.0c
176. Freeman, D., & Freeman, J. (2012). 7. Panic disorder. Anxiety. https://doi.org/10.1093/actrade/9780199567157.003.0007
177. FRIEDLANDER, A., Friedlander, I. K., Barquero, N. C., Frías, J. L., & Velasco‐Ortega, E. (2006). La atención odontológica del paciente con trastorno bipolar (psicosis maníaco-depresiva). Archivos de odontoestomatología.
178. Friese, M. B., Rothmeier, J., Willemsen, F., & Froescher, W. (2001). Subacute Encephalopathy with Seizures in Chronic Alcoholism (SESA Syndrome). Clinical Electroencephalography. https://doi.org/10.1177/155005940103200405
179. Frommann, I., Pukrop, R., Brinkmeyer, J., Bechdolf, A., Ruhrmann, S., Berning, J., Decker, P., Riedel, M., Möller, H., Wölwer, W., Gäebel, W., Klosterkötter, J., Maier, W., & Wagner, M. (2010). Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early—and Additional Memory Dysfunction in the Late—Prodromal State. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbp155
180. Frénette, É., & Dement, W. C. (2008). Psychiatric Disorders. CRC Press eBooks. https://doi.org/10.3109/9781420019926-53
181. Galili, S. F. (2019). Følger af det milde hovedtraume. Dansk Tidsskrift for Akutmedicin. https://doi.org/10.7146/akut.v2i1.104546
182. Gameleira, G. H., & Barbosa, M. L. S. (2019). MANIFESTAÇÕES ATÍPICAS DAS CRISES EPILÉPTICAS. Semana de Pesquisa do Centro Universitário Tiradentes - SEMPESq - Alagoas.
183. Ganasan, S. (2019). Managing depression in the primary care setting. Journal of Prescribing Practice. https://doi.org/10.12968/jprp.2019.1.8.388
184. Ganda, K. M. (2013). Psychiatric Conditions: Assessment of Disease States and Associated Dental Management Guidelines. https://doi.org/10.1002/9781119421450.ch52
185. García, R. G., Alvarez, M. R., & Arturo, F. (2010). Cefalea por uso excesivo de medicamentos: implicaciones clínicas y terapéuticas Medication over use headache: clinical and therapeutic implications.
186. Garofalo, F. M. (2022). Síntesis de nuevas moléculas multiobjetivo derivadas del ácido valproico con actividad anticonvulsiva. https://doi.org/10.35537/10915/163663
187. Garrabé, J., & Cousin, F. (2012). Acute and transient psychotic disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0081
188. Gautam, S., Jain, A., Gautam, M., Vahia, V., & Gautam, A. (2017). Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196975
189. Gerlach, M., Mehler‐Wex, C., & Schimmelmann, B. G. (2014). Antipsychotics. https://doi.org/10.1007/978-3-7091-1501-5_5
190. Ghaemi, S. N. (2013). Understanding Mania and Depression. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199579563.013.0047
191. Giacomo, E. D., Moretti, F., Colmegna, F., & Clerici, M. (2023). Obsessive–compulsive disorder as the onset of bipolar disorder in adolescence. Bipolar Disorders. https://doi.org/10.1111/bdi.13373
192. Giannuzzi, R., Testa, A. C., Sollazzo, F., Petrongolo, L., Bernardini, L., & Daini, S. (2013). Psychiatric emergencies (part I): psychiatric disorders causing organic symptoms.. PubMed.
193. Goikolea, J. (2008). Actualización del tratamiento del trastorno bipolar. Jano: Medicina y humanidades.
194. Goldberg, S., & Chapman, J. (2014). Practice question. Nursing Older People. https://doi.org/10.7748/nop.26.10.14.s18
195. Goldstein, T. R. (2010). Bipolar Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0134
196. González, R. M., Quesada, H. S., & Sancho, L. V. (2010). Episodio mixto secundario al uso de fluoxetina en una paciente con un transtorno afectivo bipolar no diagnosticado. Revista Médica de Costa Rica y Centroamérica.
197. González, S. M. B., Campoy, A. T., Carballeda, J. M., Pastorelli, R. V., & Vallejo, J. V. G. (2011). ¿Manía vs psicosis tóxica vs trastornos de conducta? A propósito de un caso.. Psiquiatria.com.
198. Gordon, M., & Melvin, G. (2014). Prescribing for depressed adolescents: Office decision-making in the face of limited research evidence. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.12517
199. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
200. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
201. Grunze, H., Forsthoff, A., & Born, C. (2009). Polypharmazie in der Behandlung bipolarer Störungen. https://doi.org/10.1007/978-3-211-79826-3_3
202. Gudelius, C., & Mielke, R. (2008). Fahrtuechtigkeit bei der Alzheimer-Erkrankung. SCHRIFTENREIHE FAHREIGNUNG.
203. Guerdjikova, A. I., McElroy, S. L., Barger, S. D., Barth, J., Farrelly, S., & Brohan, E. (2019). Recent Advances in Depressive Disorder.
204. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
205. Gutiérrez-Achury, A. M., Vanegas-Vidal, M., Salazar-Díaz, L. I., & Arías, G. M. A. (2009). Factores farmacológicos y no farmacológicos que afectan la adherencia al tratamiento de los pacientes esquizofrénicos dados de alta en la Unidad de Salud Mental del Hospital Universitario de Neiva entre enero y junio del 2008. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v1i2.43
206. Guzé, S. B., Martin, R. L., Cloninger, C. R., & Clayton, P. J. (1985). Frequency and differential diagnosis of depressive syndromes in schizophrenia.. PubMed.
207. Gómez‐Revuelta, M., Blanco, L. S., Ruíz, M. J., Jenaro, G. P. D. S., Rodríguez, R. L., Olivares, O. P., & Morales, N. N. (2017). A Clinical review about differential diagnosis and comorbidities on premenstrual dysphoric disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.577
208. Halvorsen, H. T., Hammer, S. K., Nystrøm, V., & Leonardsen, A. L. (2019). Delirium hos intuberte intensivpasienter. iNSPIRA. https://doi.org/10.23865/inspira.v14.2784
209. Hasanah, L. (2015). Penyakit Skizoafektif dengan Tipe Depresi pada Wanita 34 Tahun. Jurnal Medula.
210. Hattori, I., & Miyauchi, T. (2005). [Relationship between the courses of clinical Features of patients with schizophrenia in adolescents and admission to psychiatric clinic].. PubMed.
211. Hautzinger, M. (1993). Depressionen. Verhaltenstherapie. https://doi.org/10.1007/978-3-662-22591-2_63
212. Hayne, C. H., & Louks, J. L. (1991). Dysphoria in Male Alcoholics with a History of Hallucinations. The Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-199107000-00005
213. Hechtman, L. (1991). Resilience and Vulnerability in Long Term Outcome of Attention Deficit Hyperactive Disorder. The Canadian Journal of Psychiatry. https://doi.org/10.1177/070674379103600606
214. Heckers, S. (2009). Neurobiology of Schizophrenia Spectrum Disorders. Annals of the Academy of Medicine Singapore. https://doi.org/10.47102/annals-acadmedsg.v38n5p431
215. Hegel, M. T., Stanley, M. A., & Arean, P. E. (2002). Minor Depression and 'Subthreshold' Anxiety Symptoms in Older Adults: Psychosocial Therapies and Special Considerations. Generations.
216. Heinz, G. J. A. (2004). Entstehung, Diagnose und Früherkennung schizophrener Erkrankungen. psychoneuro. https://doi.org/10.1055/s-2004-823780
217. Henning, A., Kurtom, M., & Espiridion, E. D. (2019). A Case Study of Acute Stimulant-induced Psychosis. Cureus. https://doi.org/10.7759/cureus.4126
218. Hernández, O. M. O. M., & Morales, X. (2018). Fiesta neuronal: estado epiléptico en pediatría. Anales médicos (México, D.F.).
219. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
220. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
221. Hj, A., Barrucand, D., & Auzépy, P. (1993). [Alcohol withdrawal syndrome and delirium tremens. Their treatment].. PubMed.
222. Hoareau, S. (2016). Traumatismes mineurs aux urgences : relation entre le stress ressenti et la survenue d’un syndrome post-commotionnel.
223. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
224. Holmes, G. L., & Bingham, P. M. (2016). The Headache That Wouldn’t Go Away. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190601508.003.0030
225. Hosztafi, S. (2011). [Heroin addiction].. PubMed.
226. Huber, M. (2004). Forschungsschwerpunkt Sensitivierungsmodelle zu Genese und Verlauf psychiatrischer Erkrankungen. Steinkopff eBooks. https://doi.org/10.1007/978-3-7985-1957-2_30
227. Huda, A. S. (2019). Spectrums of health. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198807254.003.0009
228. Hulu, F., Manurung, J., Meylani, M., pagan, S. H., & Pardede, J. A. (2022). Penerapan Terapi Generalis SP 1- 4 Dengan Masalah Risiko Perilaku Kekerasan Pada Penderita Skizofrenia. https://doi.org/10.31219/osf.io/a26mk
229. Huprich, S. K. (2010). Schizoid Personality Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0819
230. Hybels, C. F., Blazer, D. G., & Steffens, D. C. (2006). Partial remission. A common outcome in older adults treated for major depression.. PubMed.
231. Häfner, H. (2002). Prodrome, onset and early course of schizophrenia. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544118.011
232. Håkansson, A., & Johansson, B. (2015). Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report. Journal of Medical Case Reports. https://doi.org/10.1186/s13256-015-0678-5
233. Ibrahim, I. R., & Amar, K. (2007). Mild cognitive impairment. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2007.68.10.27322
234. Iliev, B., & Pavlovska, I. (2021). Analysis of Clinical Features of Patients with Depressive Disorder. Journal of Health Medicine and Nursing. https://doi.org/10.7176/jhmn/92-01
235. Ilić, I., Kastratović, Ž., & Šaula-Marojević, B. (2004). Mood disorders with the adolescents. Engrami.
236. Ingrassia, G. F. (2012). HISTORICAL EVOLUTION OF MEDICAL KNOWLEDGE IN THE FIELD OF VEGETATIVE STATE.
237. Isenberg, K., & Garcia, K. S. (2008). Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Caused by a General Medical Condition. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-252-6_2
238. Iversen, L. L., Iversen, S. D., Bloom, F. E., & Roth, R. H. (2009). Psychedelics. Oxford University Press eBooks. https://doi.org/10.1093/med/9780195380538.003.0606
239. Izquierdo, A. Y. (2005). Crisis convulsivas. Concepto, clasificación y etiología. Emergencias: Revista de la Sociedad Española de Medicina de Urgencias y Emergencias.
240. Işık, M. (2018). Postpartum Psychosis. Eastern Journal Of Medicine. https://doi.org/10.5505/ejm.2018.62207
241. İbiloğlu, A. O., Atlı, A., Kaya, M. C., Baran, A. S., & Sır, A. (2016). Psychogenic Gait Disorder After a Stressful Life Event: Case Report. Turkiye Klinikleri Journal of Case Reports. https://doi.org/10.5336/caserep.2015-46732
242. Janicak, P. G. (2014). Pharmacological Treatment of Psychosis. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg11
243. Ji, J. (2012). Distinguishing subclinical (subthreshold) depression from the residual symptoms of major depression.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2012.05.007
244. Jibson, M. D., Glick, I. D., & Tandon, R. (2004). Schizophrenia and Other Psychotic Disorders. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/foc.2.1.17
245. Joshi, S., & Kapur, J. (2012). GABAA Receptor Plasticity during Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199746545.003.0041
246. Juruena, M. F. (2012). Understanding subthreshold depression.. PubMed. https://doi.org/10.3969/j.issn.1002-0829.2012.05.009
247. Kadaňka, Z., & Keller, O. (2013). Syndrom chronické únavy. Neurologie pro praxi.
248. Kadmaerubun, M. C., Sutejo, S., & Syafitri, E. N. (2016). HUBUNGAN KEMANDIRIAN ACTIVITY DAILY LIVING (ADL) DENGAN KUALITAS HIDUP PADA PASIEN SCHIZOPHRENIA DI POLIKLINIK JIWA RSJ GRHASIA DIY.
249. Kahn, D., & Chaplan, R. (2002). The “Good Enough” Mood Stabilizer: A Review of the Clinical Evidence. CNS Spectrums. https://doi.org/10.1017/s1092852900017594
250. Kalla, C. (2020). [SWITCH TO MANIC EPISODE WITH MIXED FEATURES IN DEPRESSIVE SOLDIER UNDER ANTIDEPRESSANT TREATMENT].. PubMed.
251. Kane, J. M. (1996). Schizophrenia. New England Journal of Medicine. https://doi.org/10.1056/nejm199601043340109
252. Kang, W.-H., Na, J., Kim, M.-K., & Yoo, B.-G. (2013). Hashimoto’s Encephalopathy Presenting with Acute Cognitive Dysfunction and Convulsion. Journal of Epilepsy Research. https://doi.org/10.14581/jer.13013
253. Kanner, A. M., & Dunn, D. W. (2004). Diagnosis and Management of Depression and Psychosis in Children and Adolescents With Epilepsy. Journal of Child Neurology. https://doi.org/10.1177/088307380401900108
254. Kanner, A. M., & LaFrance, W. C. (2006). Epilepsy. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-960-8_16
255. Karaaslan, K., Gümüş, E., Gülcü, N., & Altunrende, B. (2008). Dirençli Jeneralize Status Epileptikusun Propofol ile Tedavisi (Olgu Sunumu). Duzce Medical Journal.
256. Kasanin, J. (1933). THE ACUTE SCHIZOAFFECTIVE PSYCHOSES. American Journal of Psychiatry. https://doi.org/10.1176/ajp.90.1.97
257. Keck, P. E., Frye, M. A., & Thase, M. E. (2007). Bipolar Depression: <i>Best Practices for the Hospitalized Patient</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900015844
258. Kellett, J. M. (1993). Long term care on the NHS: a vanishing prospect.. BMJ. https://doi.org/10.1136/bmj.306.6881.846
259. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
260. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
261. Kerchner, G. A., & Rosenbloom, M. (2014). Frontotemporal Neurocognitive Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg65
262. Khaikin, Y., & Mercimek‐Andrews, S. (2016). STXBP1 Encephalopathy with Epilepsy.
263. Kihlstrom, J. F. (2010). Dissociative Disorders. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0279
264. Kim, J.-Y. (2006). 분노증세를 동반한 심인성 진전 환자에 대해 이완요법과 한방치료를 실시한 1례 보고. 동의신경정신과학회지.
265. Kim, S.-H., Park, S.-J., Byun, S.-I., Kim, J., Kim, J.-W., Chung, S.-Y., Hwang, W.-W., & Kim, J.-H. (2006). Relaxation Training for psychogenic tremor patient with anger : A Case Report. The Korean Society of Oriental Neuropsychiatry.
266. Klawans, H. L., Tanner, C. R. M., & Barr, A. (1984). The Reversibility of “Permanent” Tardive Dyskinesia. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-198406000-00006
267. Ko, J. Y., Wolicki, S. B., Barfield, W. D., Patrick, S. W., Broussard, C. S., Yonkers, K. A., Naimon, R., & Iskander, J. (2017). CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm6609a2
268. Kolla, B., & Hocker, S. E. (2021). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0045
269. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
270. Kora, K., & Kaplan, P. (2008). [Hypomania/mania induced by cessation of antidepressant drugs].. PubMed.
271. Korff, M. V., & Simon, G. (1996). The Relationship Between Pain and Depression. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000298474
272. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
273. Kreč, S. (2016). Kronična migrena kao socioekonomski problem današnjice.
274. Kroyzer, N., Hashkes, P. J., & Ben‐Pazi, H. (2015). Sydenham's chorea: Long-term immunosuppression for psychiatric symptoms. Journal of Pediatric Neurology. https://doi.org/10.3233/jpn-2012-0561
275. Kumar‐Sinha, C., Athwal, P. S. S., Gulati, A., Khan, Y., & Singh, Y. (2019). Epilepsia Partialis Continua as a Symptom of Alcohol Withdrawal in a Type 2 Diabetic Patient.. Asian Journal of Medical Research. https://doi.org/10.21276/ajmr.2019.8.2.me4
276. Kupka, R., & Goor, L. P. V. (2021). Manie en bipolaire stemmingsstoornissen. https://doi.org/10.1007/978-90-368-2586-3_11
277. Küstner, E. C., Cuéllar, H. C., & López, J. L. (2004). Introducción al síndrome de fatiga crónica (SFC). Archivos de odontoestomatología.
278. Laboudi, F., Korchi, A., & Ouanass, A. (2023). Comorbid anxiety has schizophrenia diagnosis and management modality. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1421
279. Laili, S. R. (2019). Asuhan Keperawatan Jiwa dengan Kasus Halusinasi Penglihatan di Wilayah Kerja UPTD Puskesmas Kecamatan Sananwetan Kota Blitar.
280. Lareau, S. C., & Bonnet, M. H. (1985). Sleep Disorders. The Nurse Practitioner. https://doi.org/10.1097/00006205-198508000-00004
281. Latronico, N., Antonini, L., Taricco, M., Vignolo, L., & Candiani, A. (2000). [Approach to the patient in vegetative state. Part II: differential diagnosis].. PubMed.
282. Lavoie, S., Polari, A., Goldstone, S., Nelson, B., & McGorry, P. D. (2019). Staging model in psychiatry: Review of the evolution of electroencephalography abnormalities in major psychiatric disorders. Early Intervention in Psychiatry. https://doi.org/10.1111/eip.12792
283. Lawrence, R. E., First, M. B., & Lieberman, J. A. (2015). Schizophrenia and Other Psychoses. Psychiatry. https://doi.org/10.1002/9781118753378.ch48
284. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
285. Lee, C., Kim, T. Y., Song, Y. K., Son, Y., & Cheong, Y. K. (2006). Transient Global Amnesia Developed in Recovery Room following General Anesthesia: A case report. Korean Journal of Anesthesiology. https://doi.org/10.4097/kjae.2006.51.1.130
286. Lee, E., Cheuk, J. T. Y., & Ungvári, G. S. (2009). A Patient with Chronic Schizophrenia Presenting with Multiple Deliberate Self-Harm and Genital Self-Mutilation. Hong Kong journal of psychiatry.
287. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
288. Lemoine, P. (2013). Insomnies, hypersomnies, parasomnies en psychiatrie. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.087
289. León, M. S. M. D. (2017). Trastorno por déficit de atención con hiperactividad: autorregulación emocional y funciones ejecutivas.
290. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
291. Liberalesso, P. B. N. (2018). Epileptic Syndromes in Childhood. A Practical Approach. Residência Pediátrica. https://doi.org/10.25060/residpediatr-2018.v8s1-10
292. Liddle, P. F. (2012). Descriptive clinical features of schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0072
293. Lievre, J. L., Schweitzer, R., & Barnard, A. (2012). The subjective experience of negative symptoms: Characteristics of emotional withdrawal.
294. Ligier, F., & Kabuth, B. (2016). Between Neurology and Psychiatry, a Difficult Preliminary Diagnosis of Kleine-levin Syndrome: Case-report of a Young Girl. Journal of Child and Adolescent Behaviour. https://doi.org/10.4172/2375-4494.1000274
295. ling, Z. G. (2014). 抑郁症的低动力症状特点. Chin J Psychiatry. https://doi.org/10.3760/cma.j.issn.1006-7884.2014.02.013
296. Lipton, R. B. (2011). Chronic Migraine, Classification, Differential Diagnosis, and Epidemiology. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2011.01954.x
297. Liu, S. (2011). Relationship Discussion between Emotional Factors and Chronic Fatigue Syndrome. Liaoning Zhongyiyao Daxue xuebao.
298. Llcms, L. C., Martins, P. R. C., Loures, É. N., Vitalino, A. R., Lotufo, C. C., & Onady, S. Y. (2017). ATAQUE ISQUÊMICO TRANSITÓRIO E ESTADO DE MAL EPILÉPTICO COMO MANIFESTAÇÕES DE INTOXICAÇÃO AGUDA E ABSTINÊNCIA POR CRACK E COCAÍNA.
299. Llorca, P., Chéreau, I., Brousse, G., & Schawn, R. (2004). Troubles psychiatriques d'origine toxique ou alimentaire. EMC - Psychiatrie. https://doi.org/10.1016/j.emcps.2004.04.003
300. Lochhead, J. D., Maguire, G. A., & Nelson, M. A. (2018). Pseudobulbar Affect Versus Depression: Issues in Diagnosis and Treatment.
301. Loconte, S. (2019). Primary fibromyalgia syndrome: A new holistic approach [abstract]. Journal of Ozone Therapy. https://doi.org/10.7203/jo3t.3.4.2019.15526
302. Loitman, J. E., & Deshields, T. L. (2010). Psychiatric Palliative Care Issues. Humana Press eBooks. https://doi.org/10.1007/978-1-60761-590-3_4
303. Lucchesi, L. M., Pradella-Hallinan, M., Lucchesi, M., & Moraes, W. A. D. S. (2005). O sono em transtornos psiquiátricos. Brazilian Journal of Psychiatry. https://doi.org/10.1590/s1516-44462005000500006
304. Luisetto, M. (2018). Mindset kinetics and Some Depression Status: A New Quantitative Model Under Biochemical-Toxicology Approach?. Journal of pharmacology & clinical research. https://doi.org/10.19080/jpcr.2018.05.555680
305. López, A. M., Martínez, L. R. D., & Moreno, J. (2012). Uso de marcadores bioquímicos para valoración de riesgo de crisis convulsivas en el síndrome de supresión etílica. Salud Mental.
306. Löscher, W. (2009). Molecular mechanisms of drug resistance in status epilepticus. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02367.x
307. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
308. Madrigal, J. G. T. (2012). Status epiléptico en emergencias: manejo tradicional y tendencia actual. Revista Médica de Costa Rica y Centroamérica.
309. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
310. Mahato, A. K., & Halder, S. (2016). Disability in Schizophrenia. Advances in psychology, mental health, and behavioral studies (APMHBS) book series. https://doi.org/10.4018/978-1-5225-0519-8.ch010
311. Mahesh, R., Pandey, D. K., Bhatt, S., & Gautam, B. (2010). Depression Associated Disorders: Comorbidity, eurobiological and eurobehavioural Link.
312. Maier, W., Falkai, P., & Wagner, M. (1999). Schizophrenia Spectrum Disorders: A Review. Schizophrenia. https://doi.org/10.1002/0470842334.ch5
313. Maj, M., & Perris, C. (1985). An approach to the diagnosis and classification of schizoaffective disorders for research purposes. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1985.tb02633.x
314. Majeske, M., Nistor, V., & Kellner, C. H. (2016). Late‐Life Psychosis. https://doi.org/10.1002/9781118654231.ch35
315. Malhotra, B. S., Nain, P., Sidana, J., Gupta, A., & Sharma, S. (2011). Chronic Fatigue Syndrome: A Review. HAL (Le Centre pour la Communication Scientifique Directe).
316. Mameniškienė, R., Bast, T., Bentes, C., Canevini, M. P., Dimova, P., Granata, T., Høgenhaven, H., Jakubi, B. J., Marusič, P., Melikyan, G., Michelucci, R., Мukhin, К. Y., Oehl, B., Ragona, F., Rossetti, A. O., Rubboli, G., Schubert‐Bast, S., Stephani, U., Strobel, J., ... Wolf, P. (2011). Clinical course and variability of non-Rasmussen, nonstroke motor and sensory epilepsia partialis continua: A European survey and analysis of 65 cases. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02974.x
317. Mamidi, P., & Gupta, K. (2021). Vishesha or Upa Grahonmadas: Various Psychiatric and Neuropsychiatric Conditions. International Journal of Yoga - Philosophy Psychology and Parapsychology. https://doi.org/10.4103/ijny.ijoyppp_8_20
318. Mandos, L. A., PharmD, Reinhold, J. A., Bcps, Bcpp, & Rickels, K. (2009). Achieving Remission in Generalized Anxiety Disorder.
319. Manica, A., Leães, C. G. S., Frey, B. N., & Juruena, M. F. (1999). The role of depression in coronary artery disease. Arquivos Brasileiros de Cardiologia. https://doi.org/10.1590/s0066-782x1999000800012
320. Manysheva, K., Sherman, M. A., Zhukova, N. V., & Kopishinskaia, S. (2022). Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: First Described Complication after Gam-COVID-Vac Vaccine.. PubMed.
321. Marcello, S., & Silverstein, S. M. (2010). Schizophrenia. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0820
322. Marder, S. (1996). Pharmacological treatment strategies in acute schizophrenia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199605002-00005
323. Margoles, M. S., & Hach, S. (2019). Reflex Sympathetic Dystrophy. CRC Press eBooks. https://doi.org/10.1201/9780367810979-14
324. Markham, R. A., & Watts, S. (2005). Etiology of Depression in Children.. Journal of instructional psychology.
325. Marneros, A. (2012). Schizoaffective Disorder. Korean Journal of Schizophrenia Research. https://doi.org/10.16946/kjsr.2012.15.1.5
326. Martínez, M. J. G. (2009). Identificación de marcadores en esquizofrenia y su tratamiento mediante proteómica comparativa en cerebro humano postmortem.
327. Masodkar, K., Manning, S., & McMahon, T. (2016). Bipolar II Disorder Masked by Substance Use. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.15l01813
328. Mauri, M. C. (2016). Drug Induced Psychosis or Schizophrenia?. Dual Diagnosis Open Access. https://doi.org/10.21767/2472-5048.100011
329. McGuire, B. E., & Wraith, A. E. (2000). Legal and psychological aspects of stalking: a review. Journal of Forensic Psychiatry. https://doi.org/10.1080/09585180050142543
330. McIntyre, R. S., Danielle, S., & Soczynska, J. K. (2014). Differentiating cognitive dysfunction from other dimensions of psychopathology in major depressive disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199688807.003.0005
331. McKenna, P. J., Kane, J. M., & Parrish, K. (1985). Psychotic syndromes in epilepsy. American Journal of Psychiatry. https://doi.org/10.1176/ajp.142.8.895
332. McPherson, S. (2004). Apathy in Alzheimer’s Disease. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-661-4_44
333. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
334. Melo-Dias, C., Apóstolo, J., & Cardoso, D. (2014). Effectiveness of progressive muscle relaxation training for adults diagnosed with schizophrenia: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. https://doi.org/10.11124/jbisrir-2014-1639
335. Menéndez, S. F., González, J. M. G., Antuña, V. Á., & Bobes, J. (2016). La demencia del rey Fernando VI y el año sin rey. Revista de Neurología. https://doi.org/10.33588/rn.6211.2016040
336. Messina, G., Franzini, A., Cecchini, A. P., & Leone, M. (2016). ONS and DBS for the Treatment of Chronic Cluster Headache. InTech eBooks. https://doi.org/10.5772/64482
337. Mettu, S., Animireddy, D., Kanumuri, P. K., & Muppa, R. (2016). Symptomatic management of a child with cyclic vomiting syndrome. BMJ Case Reports. https://doi.org/10.1136/bcr-2016-216499
338. Mewes, R., & Rief, W. (2008). Somatoforme Störungen und Hypochondrie. Psychiatrie und Psychotherapie up2date. https://doi.org/10.1055/s-2007-986338
339. Meza, E. G. L., Téllez, F. C., Guevara, I. M. A., González-Aragón, M. D. C. F., & Calderón, L. Á. R. (2003). Estado epiléptico no convulsivo asociado a enfermedad de Lafora: presentación de dos casos. Revista de Neurología. https://doi.org/10.33588/rn.3710.2003290
340. Michal, M. (2022). Depersonalization/Derealization Disorder. Routledge eBooks. https://doi.org/10.4324/9781003057314-29
341. Michels, R., & Marzuk, P. M. (1993). Progress in Psychiatry. New England Journal of Medicine. https://doi.org/10.1056/nejm199308263290908
342. Mignot, T., Maillard, L., Laprévote, V., Schwan, R., & Hingray, C. (2015). Crises psychogènes non épileptiques : une maladie émotionnelle ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2015.09.224
343. Miller, F. T., Abrams, T., Dulit, R., & Fyer, M. R. (1993). Psychotic Symptoms in Patients With Borderline Personality Disorder and Concurrent Axis I Disorder. Psychiatric Services. https://doi.org/10.1176/ps.44.1.59
344. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
345. Miller, N., Cocores, J. A., & Belkin, B. (1991). Nicotine Dependence: Diagnosis, Chemistry and Pharmacological Treatments. Annals of Clinical Psychiatry. https://doi.org/10.3109/10401239109147967
346. Miller, R. L., & Mason, S. E. (2011). What Is Schizophrenia?. Columbia University Press eBooks. https://doi.org/10.7312/columbia/9780231150415.003.0004
347. Mir, J. A., Mushtaq, B., & Mushtaq, O. A. (2022). Clinical case report on bipolar affective disorder, mania. IP Journal of Paediatrics and Nursing Science. https://doi.org/10.18231/j.ijpns.2022.007
348. MM, B., Islam, S., Nh, S., Rahman, M., & Bari, M. (2016). None. MOJ Orthopedics & Rheumatology. https://doi.org/10.15406/mojor.4.1
349. Moch, S. (2011). Dysthymia: more than "minor".
350. Moch, S. (2011). Dysthymia: more than “minor” depression. South African Pharmaceutical Journal.
351. Mohedano, C. R., Espárrago‐Llorca, G., & Expósito, L. C. (2011). Comorbilidad psiquiátrica en la dependencia alcohólica (II): Alucinosis alcohólica, celotipia y otros trastornos.
352. Mohr, P., & Čermák, J. (2006). Deprese u schizofrenie. Psychiatrie pro praxi.
353. Montgomery, S., Bebbington, P., Cowen, P. J., Deakin, J., Freeling, P., Hallström, C., Katona, C., King, D. S., Leonard, B., Levine, S., Phanjoo, A. L., Peet, M., Thompson, C. M., & Thompson, C. M. (1993). Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/0269881193007001041
354. Moor, C.-C., Berwanger, C., & Welter, F. L. (2002). Visuelle Pseudohalluzinationen unter Interferon-Î²1a. Aktuelle Neurologie. https://doi.org/10.1055/s-2002-33660
355. Morell, I. B. (2011). Caracterització farmacològica de moduladors gabaèrgics per al tractament de l’insomni primari. TDX (Tesis Doctorals en Xarxa).
356. Moreno, D. H., & Moreno, R. A. (2005). Estados mistos e quadros de ciclagem rápida no transtorno bipolar. Archives of Clinical Psychiatry (São Paulo). https://doi.org/10.1590/s0101-60832005000700009
357. Morin, C. (2009). [Sense of personal identity and focal brain lesions].. PubMed. https://doi.org/10.1684/pnv.2009.0156
358. Moroi, I., Iancu, M. A., Stanescu, A. A. M., Stoian, A. P., Hainăroșie, R., Socea, B., Marcu, D. T. M., Spinu, D. A., Bratu, O. G., & Diaconu, C. C. (2018). Alcohol Withdrawal Syndrome: a Review. Medicina Moderna - Modern Medicine. https://doi.org/10.31689/rmm.2018.25.2.69
359. Morylowska-Topolska, J., Ziemiński, R., Molas, A., Gajewski, J., Flis, M., Stelmach, E., & Karakuła‐Juchnowicz, H. (2016). Schizophrenia and anorexia nervosa – reciprocal relationships. A literature review. Psychiatria Polska. https://doi.org/10.12740/pp/onlinefirst/63514
360. Mossaheb, N., Schloegelhofer, M., Schaefer, M., Fusar‐Poli, P., Smesny, S., McGorry, P. D., Berger, G., & Amminger, G. P. (2012). Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-215-5_9
361. Moster, R. L., Siever, L. J., & Frangou, S. (2016). Schizophrenia Spectrum and Other Psychotic Disorders. https://doi.org/10.1002/9781118654231.ch15
362. Motta, M. P., Quadros, A. A. J., Ferreira, L. S., & Oliveira, A. S. B. (2019). Fatigue in Post-Polio Syndrome. Brazilian Journal of Biological Sciences. https://doi.org/10.21472/bjbs.061203
363. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
364. Mucci, A., Bucci, P., Giordano, G. M., Brando, F., & Galderisi, S. (2021). Apathy in schizophrenia: assessment in clinical settings and overlap with other dimensions of impairment. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2021.159
365. Musalek, M. (2022). Differences of Psychopathology of Psychiatric Disorders in Adult Patients with Intellectual Disability. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2022.176
366. Möller, H. (2004). Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie. Deutscher Universitätsverlag eBooks. https://doi.org/10.1007/978-3-322-83447-8_2
367. Na, I., & Volel, B. A. (2002). [Clinical aspects of "folie du doute"].. PubMed.
368. Nahler, G. (2009). labelling phenomenon. Dictionary of Pharmaceutical Medicine. https://doi.org/10.1007/978-3-211-89836-9_767
369. Naidu, B. M. (2016). Drug Abuse in India. International journal of research in social sciences.
370. Nakaya, M., Suwa, H., Komahashi, T., & Ohmori, K. (1999). Is Schizophrenic Symptomatology Independent of the Phase of the Illness?. Psychopathology. https://doi.org/10.1159/000029062
371. Naranđa, F. S. (2019). Značaj Empty selle u procjeni funkcije hipofize.
372. Nasrallah, H. A. (2015). Setting the Stage for Success or Failure. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.14016tx1c
373. Negueruela-López, M., Mardomingo, M. J., & Sánchez, P. G.-P. (2012). Prodromal obsessive-compulsive symptoms in a case of schizophrenia.. PubMed.
374. Nivoli, G., Lorettu, L., Veneto, L. I., Milia, P., Nivoli, L., & Nivoli, A. (2006). Problemi gestionali delle gravi manifestazioni aggressive : Criminalità e spettro dell'umore. https://doi.org/10.1400/91497
375. Noctor, E., Kennedy, K., & Corby, C. S. (2020). Manic-like presentation with an organic aetiology. Irish Journal of Psychological Medicine. https://doi.org/10.1017/ipm.2020.76
376. Novaković, M., Løhde, L. W., Brandt-Christensen, A. M., & Jørgensen, M. H. (2024). Effect of ECT on chronic fatigue syndrome. Ugeskrift for Læger. https://doi.org/10.61409/v07240476
377. Nunes, F. D. D., Freitas, P. H. B. D., Pinto, J. A. F., Souza, A. R. S., & Machado, R. M. (2016). Análise da prevalência de Síndrome Metabólica e fatores de risco associados em pacientes com Esquizofrenia Refratária. 12º Congresso Internacional da Rede Unida.
378. Ojeda, A. A. A., Li, B., & Patel, R. (2023). Substance-Induced Psychotic Disorder. Psychiatric Annals. https://doi.org/10.3928/00485713-20230314-01
379. Oliveira, C. C. D., & Feitosa, C. R. H. F. (2008). Imagens no espelho de vênus: vivências inconscientes. ID on line REVISTA DE PSICOLOGIA. https://doi.org/10.14295/idonline.v2i4.159
380. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
381. Olowoyo, P., Oguntoye, O., Akinbote, J. A., & Akinyemi, M. O. R. (2018). Recurrent Prolonged Epileptic Fugue State Misdiagnosed as Psychosis? Tale of a Middle-Aged Female Nigerian African. International Journal of Innovative Research in Medical Science. https://doi.org/10.23958/ijirms/vol02-i09/04
382. Olson, D. M., Westermarck, T., & Ekvall, S. W. (2005). Seizures And Epilepsy. https://doi.org/10.1093/oso/9780195165647.003.0010
383. Oral, T. (2005). Treatment of acute mania.. PubMed.
384. Ortiz, A., & Alda, M. (2018). The perils of being too stable: mood regulation in bipolar disorder. Journal of Psychiatry and Neuroscience. https://doi.org/10.1503/jpn.180183
385. Os, J. V., Praag, H. M. V., & Kloet, E. R. D. (2004). Stress, the brain and depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544422.010
386. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
387. Ozdemir, D., & Sahni, S. (2019). Conversion Disorder (Functional Neurological Symptom Disorder) Masquerading as Multiple Sclerosis: A Case Report. Cureus. https://doi.org/10.7759/cureus.4893
388. O’Dwyer, A.-M., & Campion, M. (2022). Anxiety and obsessional disorders. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198867135.003.0008
389. Pablo, G. S. D. (2018). Mental Capacity and Decision Making in Bipolar Disorder. Peer Reviewed Journal of Forensic & Genetic Sciences. https://doi.org/10.32474/prjfgs.2018.03.000152
390. Pachana, N. A., Laidlaw, K., Ceglowski, J., Dios, L. V. D., & Depp, C. A. (2014). Psychosis in Older Adults. Oxford University Press eBooks. https://doi.org/10.1093/oxfordhb/9780199663170.013.041
391. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
392. Palma, C. (2006). Detección precoz de signos tempranos en la esquizofrenia desde atención primaria. Jano: Medicina y humanidades.
393. Panza, F., Frisardi, V., Capurso, C., D’Introno, A., Colacicco, A. M., Seripa, D., Pilotto, A., Vendemiale, G., Capurso, A., & Solfrizzi, V. (2009). POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT–NO DEMENTIA. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.2009.02236.x
394. Parada, S. M. (2018). Mecanismos neurobiológicos e inmunes que subyacen al déficit en control inhibitorio: estudios preclínicos.
395. Park, S., Kim, Y., & Lee, J. (2012). A Case of Blonanserin-Induced Mania in Schizophrenia. Korean Journal of Schizophrenia Research. https://doi.org/10.16946/kjsr.2012.15.1.46
396. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
397. Pavlichenko, A. (2018). Negative symptoms of schizophrenia: the conceptualization and pathophysiological mechanisms. Part 1. Psikhiatriya. https://doi.org/10.30629/2618-6667-2018-77-86-96
398. Pavlović, J., Joković, S., & Hadživuković, N. (2016). The impact of dementia on the nutritional status in elderly people. PONS - medicinski casopis. https://doi.org/10.5937/pomc13-12338
399. Pedrós, A., Martí‐Almor, J., Gutiérrez, G., Tenías, J. M., & Ruescas, S. (2009). [Two-year diagnostic stability and prognosis in acute psychotic episodes].. PubMed.
400. Peitl, M. V., Prološčić, J., Zelić, S. B., Skarpa-Usmiani, I., & Peitl, V. (2011). Symptoms of agitated depression and/or akathisia.. PubMed.
401. Pellerin, J. (2004). [Affective disorders specific to ageing]..
402. Pereira, J. A. (2021). Teenager with paranoia and hallucinations preceded by a decline in academic and social functioning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0006
403. Pereira, S., & Rita, A. (2017). L’effet des crises épileptiques sur les fonctions cognitives et comportementales des modèles murins portant la mutation du gène Scn1a : implication dans le Syndrome de Dravet.
404. Perrino, C. D. D. (2009). Prevalencia de síntomas afectivos en una cohorte de pacientes con trastorno bipolar: Un estudio de seguimiento prospectivo hasta 18 meses.
405. Perrott, J., & Burry, L. (2015). Has the Drug of Choice for Treating Critical Illness Delirium Been Established?. The Canadian Journal of Hospital Pharmacy. https://doi.org/10.4212/cjhp.v68i5.1494
406. Person, C., Atkinson, J. H., Young, C., Deitch, D. A., & Treisman, G. J. (2005). Psychiatric disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0048
407. Petermann, F. (2012). Beschwerdenvalidierung. Die Rehabilitation. https://doi.org/10.1055/s-0032-1323652
408. Peveler, R. (2002). ABC of psychological medicine: Depression in medical patients. BMJ. https://doi.org/10.1136/bmj.325.7356.149
409. Phan, S. (2013). Primary or secondary? What came first and how to treat?. Mental Health Clinician. https://doi.org/10.9740/mhc.n178411
410. Pichler, W. J., & Pichler, C. E. (2009). DRESS (Drug Rash with Eosinophilia and Systemic Symptoms). Allergologie. https://doi.org/10.5414/alp32365
411. Pies, R. W. (2007). Is It Bipolar Depression? 'WHIPLASHED' Aids Diagnosis. Current psychiatry.
412. Pitchot, W., Scantamburlo, G., & Ansseau, M. (2013). [Psychiatric complications and addictions].. PubMed.
413. Pitchot, W., Scantamburlo, G., Pinto, E., & Ansseau, M. (2007). [Discontinuation syndrome associated with antidepressants].. RMLG. Revue médicale de Liège.
414. Politis, M., Wu, K., Molloy, S., Bain, P. G., Chaudhuri, К. R., & Piccini, P. (2010). Parkinson's disease symptoms: The patient's perspective. Movement Disorders. https://doi.org/10.1002/mds.23135
415. Pontius, A. A. (1993). NEUROPSYCHIATRIC UPDATE OF THE CRIME "PROFILE" AND "SIGNATURE" IN SINGLE OR SERIAL HOMICIDES: RULE OUT LIMBIC PSYCHOTIC TRIGGER REACTION. Psychological Reports. https://doi.org/10.2466/pr0.1993.73.3.875
416. Pontius, A. A. (1993). Neuropsychiatric Update of the Crime “Profile” and “Signature” in Single or Serial Homicides: Rule out Limbic Psychotic Trigger Reaction<sup>1</sup>. Psychological Reports. https://doi.org/10.1177/00332941930733pt125
417. Poornima, S. (2018). Psychology Case Record.
418. Popescu, D., Popescu, G., Lupu, G., Panus, V., Neagu-Sadoveanu, S., & Buda, O. (2010). Drugs effects on the central nervous system. Forensic implications. Romanian Journal of Legal Medicine. https://doi.org/10.4323/rjlm.2010.231
419. Porcelli, P., Laera, D., Mastrangelo, D., & Masi, A. D. (2012). Prevalence of Allostatic Overload Syndrome in Patients with Chronic Cardiovascular Disease. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000341179
420. Potter, W. Z., & Goldstein, D. (2004). Biological Theories of Depression and Implications for Current and New Treatments. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-792-5_1
421. Pozzoli, S., Altamura, A. C., & Bosi, M. (2006). Il trattamento a lungo termine della Depressione Unipolare: focus sulla terapia con Venlafaxina RP. Giornale italiano di psicopatologia/Journal of psychopathology/Italian journal of psychopathology.
422. Prasetya, E. C., Subagyo, R., Mahyuddin, M. H., Haniifah, U., Rafida, M., Hamida, A., Ramzy, M., & Prasetya, M. T. (2022). Continuously Paranoid Schizophrenia in Young Man: A Case Report. Asian Australasian Neuro and Health Science Journal (AANHS-J). https://doi.org/10.32734/aanhsj.v4i2.9165
423. Pratibha, S. (2010). Etiology of Late Onset Seizures.
424. Presečki, P., Filipčić, I., Arbanas, G., & Mimica, N. (2014). Neurocognitive disorders in DSM-5.
425. Puentes, M. C., & Martínez, C. A. L. (2011). EL TRASTORNO AFECTIVO BIPOLAR DESDE UNA PERSPECTIVA INTEGRAL. DOAJ (DOAJ: Directory of Open Access Journals).
426. Putra, H. G. S. A. (2015). GANGGUAN AFEKTIF BIPOLAR MANIA DENGAN PSIKOTIK: SEBUAH LAPORAN KASUS. DOAJ (DOAJ: Directory of Open Access Journals).
427. Pv, S., & Frolov, M. V. (1985). Psychophysiological Control of the Functional State of the Human Operator. Soviet Psychology. https://doi.org/10.2753/rpo1061-0405230468
428. Pérez, V., & Velásquez, C. C. (2006). Trastorno psicótico compartido en una madre y su hijo de 13 años. Universitas Médica.
429. Pérez, Y. M. M., Ortega, D. L. G., & Torres, S. V. L. (2022). AGITACIÓN PSICOMOTRIZ. PUERTO MADERO EDITORIAL eBooks. https://doi.org/10.55204/pmea.3.c10
430. Pérez, Á. M. S., Granados, F. J. V., Salazar, M. H., Méndez, A. Z., & Dávalos, É. M. (2005). Síndrome prefrontal ventromedial. Reporte de caso. Neurología, Neurocirugía y Psiquiatría.
431. Pérez-Rodríguez, V., Gadea, M. O., Caronna, E., & Urrutia, A. R. (2018). Clínica alucinatoria secundaria a enfermedad médica: características clínicas y manejo. DOAJ (DOAJ: Directory of Open Access Journals). https://doi.org/10.34810/psicosompsiquiatrnum0404
432. Qi, A., Han, X., Quitalig, M., Wu, J., Christov, P. P., Jeon, K., Jana, S., Kim, K., Engers, D. W., Lindsley, C. W., Rodriguez, A. L., & Niswender, C. M. (2024). The cannabinoid CB <sub>2</sub> receptor positive allosteric modulator EC21a exhibits complicated pharmacology <i>in vitro</i>. Journal of Receptors and Signal Transduction. https://doi.org/10.1080/10799893.2024.2431986
433. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
434. Rabins, P. V., & Slavney, P. R. (2008). Overview of Psychiatric Symptoms and Syndromes. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195309430.003.0008
435. Rachmani, S., & Mayasari, D. (2017). Kombinasi Farmakoterapi dan Psikoterapi Pada Pengobatan Episode Depresif Sedang Dengan Gejala Somatis. Jurnal Medula.
436. Rades, M., & Wulandari, A. J. (2016). Skizoafektif Tipe Campuran. Jurnal Medula.
437. Rahman, M. M., & Rabin, F. (2022). Assessment of Psychiatric Issues in Post-concussion Syndrome. Journal of Biomedical Research & Environmental Sciences. https://doi.org/10.37871/jbres1392
438. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
439. Ramasamy, J., Arumugam, S., & Thamizh, J. S. (2014). Atypical Delusional Content in a Case of Persistent Delusional Disorder: Freud Revisited. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.140742
440. Ramdhani, R., & Frucht, S. J. (2014). Movement disorders emergencies. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175845.028
441. Ramos, B. R. M., Martins, F. S., & Osório, E. (2022). Psychotic Cannabis Withdrawal: A Clinical Case. Cureus. https://doi.org/10.7759/cureus.31465
442. Rapagnani, M. P. (2012). Safety, Efficacy, and Patient Acceptability of Aripiprazole in the Maintenance Treatment of Bipolar Disorder. Clinical Medicine Insights Therapeutics. https://doi.org/10.4137/cmt.s7388
443. Rastogi, R., Swarm, R. A., Patel, T., & Riou, B. (2011). Case Scenario: Opioid Association with Serotonin Syndrome. Anesthesiology. https://doi.org/10.1097/aln.0b013e31823940c0
444. Reddy, M. S. (2012). The Bipolar Spectrum. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.96146
445. Reuber, M., Schachter, S. C., Elger, C. E., & Altrup, U. (2009). Conditions Associated With Epilepsy. https://doi.org/10.1093/oso/9780195379532.003.0005
446. Reula, L. M., García, H. S., & Fernández, A. P. (2017). Stressors in patients with schizoaffective disorder. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2017.01.1610
447. Rezapour, T., Wurfel, B. E., Simblett, S., & Ekhtiari, H. (2017). Neuropsychological Rehabilitation for Psychiatric Disorders. https://doi.org/10.4324/9781315629537-21
448. Rico, B. (2012). Finding a druggable target for schizophrenia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1209389109
449. Rietveld, S. (1998). Symptom Perception in Asthma: A Multidisciplinary Review. Journal of Asthma. https://doi.org/10.3109/02770909809068201
450. Rigaud, J., Lheureux, P., & Sauder, P. (2006). Prise en charge symptomatique : neurologique, respiratoire, hémodynamique et hépatique des intoxications graves par médicaments et substances illicites. Réanimation. https://doi.org/10.1016/j.reaurg.2006.08.002
451. Rikhari, P., & Kumar, A. (2021). Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A prospective 24-week study.
452. Ritz, L., Pitel, A., Vabret, F., Eustache, F., & Beaunieux, H. (2012). Alcoolodépendance : atteintes neuropsychologiques et diagnostics différentiels. Revue de neuropsychologie. https://doi.org/10.1684/nrp.2012.0227
453. Rizvi, S., Farooq, F., Shagufta, S., Khan, A., Masood, Y., & Saeed, H. (2018). Postictal Mania Versus Postictal Psychosis. Cureus. https://doi.org/10.7759/cureus.3338
454. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
455. Robles, L. R., Ivars, A., Menéndez, S. F., & Luque, A. A. (2012). Emergencias en trastornos del movimiento hipercinéticos. Revista de Neurología. https://doi.org/10.33588/rn.54s05.2012535
456. Rocha, E. A., Mehta, N., Távora‐Mehta, M. Z. P., Roncari, C. F., Cidrão, A. A. D. L., & Elías, J. (2021). Disautonomia: Uma Condição Esquecida – Parte 1. Arquivos Brasileiros de Cardiologia. https://doi.org/10.36660/abc.20200420
457. Rodrigo, M. V. L., Oliver, A. O., Monge, M. P., Fons, V. R., & Cantalejo, Y. D. (2023). Stigma of mental illness in the gypsy ethnic group. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2023.1438
458. Rodríguez, J. O. (2008). Aportaciones de aripiprazol en el tratamiento de pacientes agudos con esquizofrenia.. Psiquiatria.com.
459. Rogers, N. L., & Kloss, J. D. (2004). Medical Conditions and Diseases. CRC Press eBooks. https://doi.org/10.3109/9780203998007-6
460. Rohde, P., Lewinsohn, P. M., & Seeley, J. R. (1991). Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults.. Journal of Abnormal Psychology. https://doi.org/10.1037/0021-843x.100.2.214
461. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
462. Roncero, C., & Casas, M. (2004). Trastornos de ansiedad en patología dual.
463. Rončević-Gržeta, I., Crepulja, M. L., Grković, J., & Rebić, J. (2014). Why does Tina cry?Pseudobulbar syndrome - defferential diagnosis.
464. Roselló, A. P. (2005). Psicosis posparto y evolución clínica. Estudio de seguimiento hasta 10 años. A propósito de dos casos. Anales de psiquiatría.
465. Roy, M., Demers, M., & Achim, A. M. (2018). Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity. Journal of Psychiatry and Neuroscience. https://doi.org/10.1503/jpn.180081
466. Rubiales, Á. S., Duarte, F. J. B., & Valle, M. L. D. (2015). Es necesario precisar el concepto de sedación. Cuadernos de bioética/Cuadernos de bioética.
467. Rudolf, G. A. E. (2000). Diagnostische und therapeutische Maßnahmen bei einzelnen schizophrenen Syndromen und in bestimmten krankheitsbedingten Situationen. Deutscher Universitätsverlag eBooks. https://doi.org/10.1007/978-3-322-85177-2_7
468. Ruiz-Padrino, N., & Andrés-Tauler, J. M. (2014). Episodio hipomaniaco secundario al tratamiento con claritromicina en paciente adolescente. Revista de Psiquiatría Infanto-Juvenil.
469. Saaresranta, T., Polo‐Kantola, P., & Polo, O. (2013). Practical Approach for the Diagnosis and Management of Insomnia During Menopausal Transition. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-324-4_19
470. Sabin, T. D. (1998). Chronic Fatigue Syndrome. Neurology. https://doi.org/10.1212/wnl.51.1.331-a
471. Sabo-Graham, T., & Seay, A. R. (1998). Consultation with the Specialist: Management of Status Epilepticus in Children. Pediatrics in Review. https://doi.org/10.1542/pir.19.9.306
472. Sadiq, H., & Abakah, S. (2015). Depression and Its Relation with Blood Group According Differences (Sex).
473. Saeed, S. A. (2009). Social Anxiety Disorder: An Update on Evidence-Based Treatment Options.
474. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
475. Saitz, R. (1998). Introduction to alcohol withdrawal.. PubMed.
476. Sakuta, M. (2004). [Headache originating front-orbital area].. PubMed.
477. San, L., Herrero, R. M. D., & Martí, B. A. (2004). Aspectos generales de la patología dual.
478. Sanz, G. L., Ruíz, E. C., & Vázquez, L. S. (2015). Síndrome confusional ag udo en pacientes de edad avanzada con fractura de fémur. Ágora de enfermería.
479. Sari, M. N., Sulyaman, S., Sulistiono, A., & Ramadhian, M. R. (2016). Gangguan Kepribadian dan Perilaku Akibat Penyakit, Kerusakan, dan Disfungsi Otak pada Pria Usia 45 Tahun. Jurnal Medula.
480. Sayar, K., & Güzelhan, Y. (2002). Bereavement mania and its treatment: A case presentation -. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology.
481. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
482. Schildkrout, B. (2014). Delusional Thought Content. https://doi.org/10.1002/9781394260447.ch7
483. Schildkrout, B. (2014). Disease #4: Alzheimer's Disease. https://doi.org/10.1002/9781394260447.ch32
484. Schildkrout, B. (2014). Disease #53: Postconcussion Syndrome. https://doi.org/10.1002/9781394260447.ch81
485. Schildkrout, B. (2014). Disease #61: Systemic Lupus Erythematosus. https://doi.org/10.1002/9781394260447.ch89
486. Schildkrout, B. (2014). Disease #63: Thiamine Deficiency. https://doi.org/10.1002/9781394260447.ch91
487. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
488. Schildkrout, B. (2014). Mood, Affect, and Emotion. https://doi.org/10.1002/9781394260447.ch4
489. Schredl, M., Schramm, F., Valli, K., Mueller, E. M., & Sandman, N. (2020). Nightmare Distress Questionnaire: associated factors. Journal of Clinical Sleep Medicine. https://doi.org/10.5664/jcsm.8824
490. Schultze‐Lutter, F. (2016). First Signs of Emerging Psychosis. Key issues in mental health (Online)/Key issues in mental health (Print). https://doi.org/10.1159/000440912
491. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
492. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
493. Selwood, L. (2015). Adherence in schizophrenia. Mental Health Matters.
494. Serrano, J. L., Vila, S., Vidal, R. C., Padilla, E. B., Lamora, N. S., Mollà, L., Rodríguez, A. M., & López, L. M. M. (2017). COMORBILIDAD ENTRE DEPRESIÓN Y CONDUCTAS IMPULSIVAS: UN CASO DE URGENCIA NEGATIVA.
495. Sewart, A. R., & Craske, M. G. (2018). Panic Disorder and Agoraphobia. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190492243.003.0013
496. Sh.H., S., L.A., T., N.I., K., V.K., A., & Nurkhodjaev, S. (2020). Diagnostics of Dysthymic Disorders and Therapy of Patients with Opium Addiction with AnxietyDepressive Variant of Post-Withdrawal Syndrome. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.122320
497. Shah, M. S., Parikh, D., & Karia, S. (2018). Depot preparation in schizophrenia: Indian outlook. Annals of Indian Psychiatry. https://doi.org/10.4103/aip.aip_41_18
498. Sharabyani, S. M. (2016). MENTAL DISORDER AND THEIR TREATMENT. Journal of Fundamental and Applied Sciences. https://doi.org/10.4314/jfas.v8i3s.388
499. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
500. Sheehan, B., Karim, S., & Burns, A. (2009). Paranoid illness and schizophrenia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199216529.003.0006
501. Sheets, E. S., & Brosse, A. L. (2010). Major Depressive Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0522
502. Shejekar, S., Nemlekar, S., & Srivastava, A. (2019). Organic mood disorder: Sequelae of small vessel disease. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_357_18
503. Shih, T., & Bazil, C. W. (2005). Treatment of Generalized Convulsive Status Epilepticus. Humana Press eBooks. https://doi.org/10.1385/1-59259-945-1:265
504. Shorvon, S. (2011). Super‐refractory status epilepticus: An approach to therapy in this difficult clinical situation. Epilepsia. https://doi.org/10.1111/j.1528-1167.2011.03238.x
505. Sievers, M., Sato, T., Möller, H.-J., & Bottlender, R. (2005). Obsessive-compulsive Disorder (OCD) with Psychotic Symptoms and Response to Treatment with SSRI. Pharmacopsychiatry. https://doi.org/10.1055/s-2005-837814
506. Silver, R. M., & Airoldi, J. (2016). 27. Inherited thrombophilia. CRC Press eBooks. https://doi.org/10.1201/9781315200910-28
507. Singh, G., & Akinyemi, E. (2017). Managing Manic Delirium in Bipolar Disorder With Features of Mania, Catatonia, and Neuroleptic Malignant Syndrome. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.17l02149
508. Singh, R., & Chaudhury, S. (2009). Hyponatremia-induced psychosis in an industrial setting. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.62277
509. Sinha, R., & Singh, S. (2021). Clinical and Electroencephalogram Correlation of Self-Limited Epilepsy with Autonomic Seizures. Indian Pediatrics Case Reports. https://doi.org/10.4103/ipcares.ipcares_287_21
510. Sireesha, S. R., Boorla, V., & Bhogaraju, A. (2013). Prolonged delirium secondary to hypoxic ischemic encephalopathy following complete hanging. Archives of Mental Health. https://doi.org/10.4103/2589-9171.227665
511. Smith, J. R. (2021). An episode of giddy, irritable mood with increased energy and goal-directed activity. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0008
512. Soares, W. B., & Lima, A. M. D. O. (2024). First Episode of Psychosis. Advances in medical technologies and clinical practice book series. https://doi.org/10.4018/979-8-3693-0851-6.ch005
513. Sommer, I. E., Koops, S., & Blom, J. D. (2012). Comparison of auditory hallucinations across different disorders and syndromes. Neuropsychiatry. https://doi.org/10.2217/npy.12.2
514. Sousa, C. D. (2007). Oral Communication 4, Monday Sept. 24th 5.00 pm-6.00 pm; Room: Lecture Hall 1: Attention, emotion and Behavior--Part 2. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agm116
515. Srivastav, D., & Singh, T. B. (2016). Comorbidity Issues and Treatment in Chronic Mental Illness. Advances in psychology, mental health, and behavioral studies (APMHBS) book series. https://doi.org/10.4018/978-1-5225-0519-8.ch005
516. Stankewicz, H., Richards, J. R., & Salen, P. (2017). Alcohol Related Psychosis. StatPearls.
517. Stecher, S. (2018). Understanding Disorders of Mood exploring the differences between Disorders of Thought and Mood.
518. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
519. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
520. Stojaković, M., Vukadinović, S., & Stojanović, Z. (2017). STRES KAO FAKTOR RIZIKA U NASTANKU DEPRESIJE NAKON MOŽDANOG UDARA. Psymedica. https://doi.org/10.7251/psy1201016v
521. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
522. Stone, R. H., McCoy-Hill, C., Holbrook, T. L., Wilson, W. C., & Hoyt, D. B. (2007). Post-traumatic Stress Disorder in Trauma and Critical Care. CRC Press eBooks. https://doi.org/10.3109/9781420016840-73
523. Stovner, L. (2009). Whiplash headache: Does the diagnosis make more harm than the whiplash?. Cephalalgia. https://doi.org/10.1111/j.1468-2982.2009.02013.x
524. Strain, J. J., Klipstein, K., & Newcorn, J. H. (2008). Adjustment Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch81
525. Stringaris, A., & Krieger, F. (2013). Bipolar disorder and disruptive mood dysregulation in children and adolescents: assessment, diagnosis and treatment. Evidence-Based Mental Health. https://doi.org/10.1136/eb-2013-101400
526. Stumpf, B. P., & Rocha, F. L. (2010). Síndrome de Diógenes. Jornal Brasileiro de Psiquiatria. https://doi.org/10.1590/s0047-20852010000200012
527. Suarez, J. M. (2018). ESQUIZOFRENIA CON SÍNTOMAS NEGATIVOS Y TEC: REPORTE DE CASO. Revista Edu-Física.
528. Sugimoto, A., Futamura, A., & Kawamura, M. (2012). [Epilepsy and dementia].. PubMed.
529. Sumiyoshi, T., Matsuoka, T., & Kurachi, M. (2012). Role for Pituitary Neuropeptides in Social Behavior Disturbances of Schizophrenia. InTech eBooks. https://doi.org/10.5772/52326
530. Summers, C. B. (2007). Cognitive-Behavior Group Therapy in Residential Treatment. https://doi.org/10.4324/9780203941157-16
531. Swann, A. C. (2009). Pharmacologic Mood Destabilization: <i>Case Vignettes</i>. CNS Spectrums. https://doi.org/10.1017/s1092852900003898
532. Swann, A. C. (2011). Diagnosis and Treatment of Mixed States. https://doi.org/10.1002/9780470975114.ch19
533. Szkodny, L. E., Jacobson, N. C., Llera, S. J., & Newman, M. G. (2014). Generalized Anxiety Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg19
534. Szortyka, M. F., Cristiano, V. B., & Belmonte-de-Abreul, P. (2021). The importance of physical intervention in the treatment of patients diagnosed with Schizophrenia. Clinical Psychiatry. https://doi.org/10.36648/2471-9854.21.7.82
535. Szyguła‐Jurkiewicz, B., Szymik, M., Mrozowska, B., Schmidt, B., & Michalak, A. (2011). Psychologiczne uwarunkowania i konsekwencje ostrego zawału serca. Leki psychotropowe u chorych po ostrym zawale serca. Choroby Serca i Naczyń.
536. Sánchez, J. M. (2014). Responsabilidad penal del drogodependiente. Revista electrónica de ciencia penal y criminología.
537. Tabbane, K., Triki, R., Hajeri, S., Johnson, I., & Chérif, W. (2012). P-1319 - Prodromal symptoms of schizophrenia: a retrospective tunisian study. European Psychiatry. https://doi.org/10.1016/s0924-9338(12)75486-x
538. Tamminga, C. A., Buchanan, R. W., & Gold, J. M. (1998). The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803003-00004
539. Tan, B. L. W., & Gudi, A. (2021). A rare case: Mania associated with pazopanib. Proceedings of Singapore Healthcare. https://doi.org/10.1177/20101058211023778
540. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
541. Tarabeih, M. (2018). Mental Disorders, Addictions Related To Long Hospitalization Days That Require Double Diagnosis in Moldova. Biomedical Journal of Scientific & Technical Research. https://doi.org/10.26717/bjstr.2018.05.0001140
542. Tariq, F. (2012). Premature Ejaculation Re-Visited: Definition and Contemporary Management Approaches. InTech eBooks. https://doi.org/10.5772/25670
543. Taska, L. S., Reynolds, C. F., Sewitch, D. E., Restifo, K., Coble, P. A., & Kupfer, D. J. (1984). Persistent psychophysiologic insomnia: preliminary Research Diagnostic Criteria and EEG sleep data. American Journal of Psychiatry. https://doi.org/10.1176/ajp.141.6.804
544. Tatsuzawa, Y., Ono, Y., Takahashi, T., Yoshino, A., & Nomura, S. (2011). Case of isolated adrenocorticotropic hormone deficiency mimicking major depressive disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2011.02207.x
545. Tatulian, S. E., Vasiliev, S. V., Yavorskaya, V. V., & Zheltyakova, Z. A. (2005). The Influence of Somatoneurological Decompensations in the Course of Old-Age Depressive Disorders. International Journal of Mental Health. https://doi.org/10.2753/imh0020-7411340410
546. Taylor, M. A. (1999). Bipolar Mood Disorders. https://doi.org/10.1093/oso/9780195130379.003.0008
547. Taylor, M. A. (1999). Personality And Personality Disorders. https://doi.org/10.1093/oso/9780195130379.003.0006
548. Tedyanto, E. H., Adnyana, I. M. O., & Widyadharma, I. P. E. (2023). Tension-type Headache and Migraine as Manifestations of Chronic Post-Traumatic Headache. Cermin Dunia Kedokteran. https://doi.org/10.55175/cdk.v50i2.528
549. Terman, M., & Terman, J. S. (2013). Chronotherapeutics. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.026
550. Terrés-Jiménez, B., Domínguez-Cabañero, E. M., González-Vivas, C., García-Parreño, B., Diego-Castaño, S., Gesler, M. A., Entrambasaguas, M. D., & Lorente-Rovira, E. (2022). Variables associated with the success of group cognitive behavioral therapy for insomnia: preliminary results.. PubMed.
551. Thaker, K. (2007). ICU Pain, Anxiety, Agitation, Delirium: In Search of the Holy Grail. Methodist DeBakey Cardiovascular Journal. https://doi.org/10.14797/mdcvj.101
552. Thase, M. E. (2005). Bipolar Depression: Issues in Diagnosis and Treatment. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220500326425
553. Thomas, H. (1993). Psychiatric Symptoms in Cannabis Users. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.163.2.141
554. Thomas, P. (2003). Non convulsive status epilepticus of frontal origin. Epileptic Disorders.
555. Thomas, P. (2003). Treatment options for acute mania. European Psychiatry. https://doi.org/10.1016/s0924-9338(03)80011-1
556. Thompson, P. J., & Trimble, M. (1996). Neuropsychological Aspects of Epilepsy. https://doi.org/10.1093/oso/9780195090734.003.0012
557. Thomsen, T., & Miyasaki, J. M. (2012). Psychogenic Movement Disorders. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-120-2_7
558. Thyer, B. A., & Wodarski, J. S. (2007). Social work in mental health : an evidence-based approach. Wiley eBooks.
559. Tiller, J., & Schweitzer, I. (2010). Bipolar disorder: diagnostic issues. The Medical Journal of Australia. https://doi.org/10.5694/j.1326-5377.2010.tb03889.x
560. Todorov, S., & Arnaoudova, M. (2011). DYNAMIC OF PARANOID SYNDROMES IN SCHIZOPHRENIA IN DEPENDENCE ON DELUSIONS OF BEING CONTROLLED. Journal of IMAB - Annual Proceeding (Scientific Papers). https://doi.org/10.5272/jimab.2011171.172
561. Todorović, S. (2016). Socijalno medicinske karakteristike i razlike između alkoholičara sa periodičnim i kontinuiranim pijenjem / Social and Medical Characteristics and Differences Between Alcoholics With Periodic and Continuous Drinking. SESTRINSKI ŽURNAL. https://doi.org/10.7251/sez0116005t
562. Torre, J. L. F., Pérez, R. G., & Zarzosa, M. V. (2003). Estado epiléptico no convulsivo. Revista de Neurología. https://doi.org/10.33588/rn.3708.2003146
563. Toudou‐Daouda, M., Assadeck, H., Obenda, N. S., & Souirti, Z. (2017). Céphalées épileptiques isolées : revue de la littérature. Isolated epileptic headache : review. African & Middle East Epilepsy Journal.
564. Touze, M.-D., Potel, G., & Baron, D. (1993). [Acute ethyl alcohol intoxication].. PubMed.
565. Townsend, M. C. (2004). Nursing diagnoses in psychiatric nursing : care plans and psychotropic medications. F.A. Davis Co. eBooks.
566. Treiman, D. M. (1993). Generalized Convulsive Status Epilepticus in the Adult. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb05902.x
567. Treiman, D. M. (1996). Status epilepticus.. PubMed.
568. Tsai, L., & Liou, H. (2015). Current Treatment for Generalized Convulsive Status Epilepticus in Adults.. PubMed.
569. Tso, I. F., Chun, J., & Deldin, P. J. (2010). Schizoaffective Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0818
570. Tw, M. (1985). Recognition of pseudodementia.. PubMed.
571. Utari, F. P., Suyanti, T. S., & Karyawati, T. (2023). Asuhan Keperawatan Jiwa Pada Tn.M Dengan Masalah Utama Resiko Perilaku Kekerasan Akibat : Skizofrenia Tak Terinci Di Ruang Srikandi RSJD Dr.Amino Gondohutomo Provinsi Jawa Tengah. DIAGNOSA Jurnal Ilmu Kesehatan dan Keperawatan. https://doi.org/10.59581/diagnosa-widyakarya.v1i4.1305
572. Utiumi, M. A. T., Munhoz, R. P., Cartaxo, C., & Teive, H. A. G. (2012). Complex movement disorder in an elderly patient and the chimera effect. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1590/s0004-282x2012000500014
573. Vamsi, M., Prasad, K. S., Rajendhar, S., & Raviteja, I. (2022). Abstract- Poster. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.341972
574. Varghese, R., John, D., & Arun, M. (2007). A case of primary hypersomnia. Annals of Indian Academy of Neurology. https://doi.org/10.4103/0972-2327.31489
575. Vega-Gorgoso, O. F. D. L. (2012). Una distimia subafectiva. Revista gallega de psiquiatría y neurociencias.
576. Velasco-Rey, M. C., Sánchez-Muñoz, M., Lopez, M., Trujillo-Borrego, A., & Sánchez-Bonome, L. (2012). Psychotic depression induced by Obstructive Sleep Apnoea Syndrome (OSAS): a case reported.. PubMed.
577. Vicente, J. F. M. (2014). Estado epiléptico refractario en el entorno de la terapia intensiva. Medicina Crítica.
578. Vidić, M. (2018). Psihološki aspekti ovisnosti o psihoaktivnim tvarima.
579. Vigevano, F., & Bartuli, A. (2002). Infantile epileptic syndromes and metabolic etiologies.. PubMed.
580. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
581. Vilke, G. M., & Ly, B. T. (2022). Clinical Syndromes and Emergency Room Physician and Management Issues. CRC Press eBooks. https://doi.org/10.4324/9781315155159-1
582. Volpe, F. M., & Tavares, A. (2000). Cyproterone for Hypersexuality in a Psychotic Patient with Wilson's Disease. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1080/j.1440-1614.2000.0822l.x
583. Wakefield, J. C., & Schmitz, M. F. (2014). Uncomplicated depression is normal sadness, not depressive disorder: further evidence from the NESARC. World Psychiatry. https://doi.org/10.1002/wps.20155
584. Walder, D. J., Statucka, M., Daly, M., & Yaffe, B. (2014). Psychotic Disorders. Psychology. https://doi.org/10.1093/obo/9780199828340-0151
585. Walker, M., Hall, K. S., Peppercorn, K., & Tate, W. P. (2022). The significance of oxidative stress in the pathophysiology of Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Medical Research Archives. https://doi.org/10.18103/mra.v10i9.3050
586. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
587. Wanigasinghe, J., Mettananda, S., & Arachchi, D. K. (2011). A case of Kleine-Levin syndrome. Ceylon Medical Journal. https://doi.org/10.4038/cmj.v56i3.3611
588. Watanabe, M. D., PharmD, & Bcpp (2007). Bifeprunox: A partial dopamine-receptor agonist for the treatment of schizophrenia. Formulary.
589. Weaver, M. (2018). Substance-Related Disorders. American Psychiatric Association Publishing eBooks. https://doi.org/10.1176/appi.books.9781615371990.jl16
590. Weaver, M. F., Heads, A. M., & Faillace, L. A. (2024). Mood Disorders and Comorbid Substance Use Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9781108973922.013
591. Weekly, S. M. (2004). Chronic fatigue syndrome (cfs). Schweizerische medizinische Wochenschrift. https://doi.org/10.4414/smw.2004.10213
592. Weisholtz, D. S., & Dworetzky, B. A. (2014). Epilepsy and Psychosis.
593. Wichaidit, B. T., Rask, C. U., & Østergaard, J. R. (2014). [Diagnosing functional seizures in children and adolescents].. Research Portal Denmark.
594. Wikinski, S. (2004). [Depression and anxiety: from clinic to pharmacological treatment].. PubMed.
595. Williams, M. D. (2018). Dynamique de l’excitabilité corticale dans l’épilepsie-absence et intégration sensorielle.
596. Wing, Y. K., & Leung, C. M. (2012). Mental health impact of severe acute respiratory syndrome: a prospective study.. PubMed.
597. Winokur, G. (1970). Genetic Findings and Methodological Considerations in Manic Depressive Disease. The British Journal of Psychiatry. https://doi.org/10.1192/s0007125000193237
598. Wolf, A., & Pajonk, F.-G. (2012). Psychische Störungen in der Intensivmedizin - Teil 1: Grundlagen, Störungsbilder und Diagnostik. AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie. https://doi.org/10.1055/s-0032-1307462
599. Wolf, P. (1993). Use of Antiepileptic Drugs in Epileptology with Respect to Psychiatry. Neuropsychobiology. https://doi.org/10.1159/000118967
600. Wright, C., & Burns, T. (2002). Management of serious mental illness. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198508946.003.0014
601. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
602. Yersin, B. (1999). [Ambulatory management of alcohol withdrawal syndrome].. PubMed.
603. Young, W. B., Packard, R. C., & Katsarava, Z. (2007). Headaches Associated with Head Trauma. https://doi.org/10.1093/oso/9780195326567.003.0016
604. Yung, A. R., Phillips, L., & McGorry, P. D. (2006). Prodromal period: pharmacological and behavioural interventions. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198510840.003.0011
605. Yutzy, S. H. (2015). Somatic Symptom and Related Disorders: Somatic Symptom Disorder, Illness Anxiety Disorder, and Conversion Disorder. Psychiatry. https://doi.org/10.1002/9781118753378.ch62
606. Zaccherini, G., Tufoni, M., Ricci, C. S., Tovoli, A., Napoli, L., & Domenicali, M. (2013). A look at the hepatic encephalopathy in cirrhosis. Reviews in Health Care. https://doi.org/10.7175/rhc.4474155-74
607. Zaccherini, G., Tufoni, M., Ricci, C. S., Tovoli, A., Napoli, L., & Domenicali, M. (2013). A look at the hepatic encephalopathy in cirrhosis. Reviews in Health Care. https://doi.org/10.7175/rhc.v4i1.447
608. Zhang, J., & Zhou, X.-Z. (2014). Recent advance in nonconvulsive status epilepticus. Chinese Journal of Neuromedicine. https://doi.org/10.3760/cma.j.issn.1671-8925.2014.04.026
609. Zn, A., & Na, A. (2005). [Psychopathology of self-consciousness in acute alcoholic hallucinosis].. PubMed.
610. Zolas, P. T., & Sher, A. (2013). Antipsychotic drugs: A review with a focus on QT prolongation. Journal of Pharmacy and Alternative Medicine.
611. Zutshi, A., Math, S. B., & Reddy, Y. C. J. (2007). Escitalopram in Obsessive-Compulsive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611c
612. Zwicker, A., MacKenzie, L. E., Drobinin, V., Vallis, E. H., Patterson, V. C., Stephens, M., Cumby, J., Propper, L., Abidi, S., Bagnell, A., Schultze‐Lutter, F., Pavlová, B., Alda, M., & Uher, R. (2019). Basic symptoms in offspring of parents with mood and psychotic disorders. BJPsych Open. https://doi.org/10.1192/bjo.2019.40
613. Öngür, D., Beneš, F. M., Freudenreich, O., Keshava, M., & McCarley, R. W. (2021). Schizophrenia Spectrum and Other Psychotic Disorders. Cambridge University Press eBooks. https://doi.org/10.1017/9780511846403.005
614. Češková, E., & Kučerová, H. P. (2018). Kognitivní dysfunkce u deprese.
615. Češková, E., Přikryl, R., Kašpárek, T., & Kučerová, H. (2008). Aggression in first-episode schizophrenia. Primary Care and Community Psychiatry.